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on the magnitude and statistical significance (or
precision) of the estimated effect of an educational
intervention, to investigate the mechanisms of
contamination, and to consider how contamination 
can be avoided.
Data sources: Major electronic databases were
searched up to May 2005.
Methods: An exploratory literature search was
conducted. The results of trials included in previous
relevant systematic reviews were then analysed to see
whether studies that avoided contamination resulted in
larger effect estimates than those that did not. Experts’
opinions were elicited about factors more or less likely
to lead to contamination. We simulated contamination
processes to compare contamination biases between
cluster and individually randomised trials. Statistical
adjustment was made for contamination using
Complier Average Causal Effect analytic methods, 
using published and simulated data. The bias and power
of cluster and individually randomised trials were
compared, as were Complier Average Causal Effect, 
intention-to-treat and per protocol methods of analysis. 
Results: Few relevant studies quantified contamination.
Experts largely agreed on where contamination was
more or less likely. Simulation of contamination
processes showed that, with various combinations of
timing, intensity and baseline dependence of
contamination, cluster randomised trials might produce
biases greater than or similar to those of individually
randomised trials. Complier Average Causal Effect
analyses produced results that were less biased than
intention-to-treat or per protocol analyses. They also
showed that individually randomised trials would in
most situations be more powerful than cluster
randomised trials despite contamination. 
Conclusions: The probability, nature and process of
contamination should be considered when designing
and analysing controlled trials of educational
interventions in health. Cluster randomisation may or
may not be appropriate and should not be uncritically
assumed always to be a solution. Complier Average
Causal Effect models are an appropriate way to adjust
for contamination if it can be measured. When
conducting such trials in future, it is a priority to report
the extent, nature and effects of contamination.
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Objectives
The objectives of the study were to consider the
effects of contamination on the magnitude and
statistical significance (or precision) of the
estimated effect of an educational intervention, 
to investigate the mechanisms of contamination,
and to consider how contamination can be
avoided.
Background
Educational interventions aimed at improving
health, knowledge or health-related behaviour
may be delivered to patients, health professionals
or members of the general public. Contamination
in controlled trials occurs when people who were
not intended to receive an intervention
inadvertently do so. Trials of educational
interventions are especially prone to
contamination because the active ingredients can
be transportable and difficult to confine.
Contamination tends to reduce the magnitude of
effect estimates and therefore also to increase the
chance that estimates will not be statistically
significant. That is, contamination causes bias and
reduces power. 
Contamination can be avoided during the design,
conduct or analysis of trials, but such strategies
may be ineffective or may be in conflict with 
each other. With cluster randomised trials, 
groups of people are allocated to receive or 
not to receive an intervention, or to receive
different interventions. This reduces
contamination bias if it effectively separates
people and so reduces the risk or extent of
contamination. However, if, within each group,
individuals are very similar to each other,
compared with individuals in other groups, then
the statistical significance and precision of effect
estimates are reduced. Various methods of data
analysis may adjust for this bias if the extent of
contamination is known. However, these
adjustments may reduce power and precision
because they exclude part of the study sample, or
they may cause bias by comparing dissimilar
subgroups of the sample. Contamination is often
assumed to be a problem when interpreting or
designing trials of educational interventions, 
but whether it really is a problem is not well
known. It has been argued that the problems of
contamination have been exaggerated, and
therefore cluster randomised trials are often
inappropriate, given their statistical disadvantages.
However, cluster randomisation may be
appropriate if interventions are aimed at
professionals or facilities that manage groups of
people, regardless of contamination. 
Methods
An exploratory literature search was conducted
with major electronic databases being searched up
to May 2005. The results of trials included in
previous relevant systematic reviews were then
analysed to see whether studies that avoided
contamination resulted in larger effect estimates
than those that did not. Experts’ opinions were
elicited about factors more or less likely to lead to
contamination. We simulated contamination
processes to compare contamination biases
between cluster and individually randomised
trials. Statistical adjustment was made for
contamination using Complier Average Causal
Effect analytic methods, using published and
simulated data. The bias and power of cluster and
individually randomised trials were compared, as
were Complier Average Causal Effect, intention-
to-treat and per protocol methods of analysis. 
Results
Literature search
Although many studies have reported using cluster
randomisation to avoid contamination, few have
quantified contamination and its effects. We
compared the results of cluster and individually
randomised trials from previous systematic reviews
of educational interventions aimed at health
professionals and at patients. We examined
whether individually randomised trials tended to
show smaller effects, which could indirectly
indicate contamination bias. This was true for the
relatively few trials that evaluated very similar
interventions, although there may be explanations
other than contamination or its avoidance. It was
Executive summaryExecutive summary
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not true for the larger number of heterogeneous
trials. One interesting trial randomised patients
either to a cluster or an individually randomised
sub-trial, both of which evaluated the same oral
health intervention. Its results suggested that
cluster randomisation reduced contamination 
bias, but some partial contamination also occurred
in the cluster randomised trial. The results could
also be explained by unblinded outcome
measurement. 
Consensus of expert opinion
Thirty-seven experts in trials of educational
interventions took part in a Delphi study. They
answered a questionnaire ranking the likelihood
that contamination would occur in various
situations, assuming for each situation that all
other factors were constant; 27 completed the
second-round questionnaire after feedback on all
responses to the first round. In the experts’
opinion, contamination was more likely in trials
conducted in settings where subjects worked, lived
or interacted closely together and where
interventions were desirable, simple or easily
transferable or were aimed at increasing
knowledge. It was less likely when subjects were
socially or physically separate, and where
interventions were complex or aimed at changing
behaviours. It was more likely with interventions
aimed at health professionals than with
interventions aimed at patients. It was more likely
with interventions based on broadcast media,
audiovisuals or written information and was least
likely with computer-based reminders. Cluster
randomisation was the design most likely to avoid
contamination and individual randomisation was
least likely to do so. 
Simulating contamination
A computer model simulated the process of
contamination to compare bias between cluster
and individually randomised trials. When
contamination is not cluster-wide but filters slowly
amongst individuals, a cluster randomised design
produces less bias. Individual randomisation
produces less bias if entire clusters are
contaminated at once, unless the risk of clusters
being contaminated is low. Different combinations
of the components of the contamination process
favour either cluster or individual randomisation
and should be considered when designing trials.
Empirical evidence of the process of
contamination during educational trials would be
valuable. 
Dealing with contamination using
Complier Average Casual Effect analysis
Intention-to-treat analysis only answers the
question of whether the offer of treatment to the
intervention population is effective. Per protocol or
on-treatment analyses, which attempt to account
for contamination or non-adherence, are likely to
be biased because of systematic differences between
exposed and unexposed control subjects. Complier
Average Causal Effect (CACE) analysis potentially
overcomes these problems. It can be implemented
in various ways. In this work, we used an
instrumental variable technique entailing a two-
stage regression. In the first stage, a dummy
variable representing the treatment that the
participants actually receive is regressed on a
dummy variable representing the treatment to
which the participants were randomised. Then in
the second stage, the outcome is regressed on the
treatment received variable and the residuals saved
from the first stage. CACE tends to produce an
unbiased estimate of the true treatment effect but
also tends to reduce statistical power. To assess
whether or not the power lost due to CACE
analysis was better or worse than that due to cluster
randomisation, we undertook a simulation exercise.
With up to 30% contamination and using a CACE
approach, individual randomisation was more
powerful than cluster randomisation. This was true
even when assuming small cluster sizes and
intracluster correlation coefficients. Although
analysis by intention-to-treat is generally the most
valid primary analytic method for randomised
trials, these methods may be appropriate for
secondary analysis of randomised trials, or for
analysis of non-randomised trials, if contamination
has been measured. 
Conclusions
The literature search found little evidence that
contamination really is a problem in trials of
educational interventions in health because very
few studies reported whether contamination
occurred. However, there is consensus about the
types of situation in which contamination is more
or less likely. If it is likely then cluster
randomisation may reduce contamination unless
entire clusters are contaminated. CACE analysis
may reduce bias if contamination is measured. In
future trials of educational interventions in health,
it is a priority to report the extent, nature and
effects of contamination.T
he purpose of a controlled trial is to obtain a
valid and precise estimate of the effect of one
or more interventions. Controlled trials typically
compare a group of individuals who have been
exposed to an intervention with a group who have
not been exposed, or have been exposed to
another intervention. Ideally, randomisation is
used to allocate individuals to the groups to be
compared. This means that the groups can be
considered to be identical, on average, at the start
of the trial. Therefore, any difference in outcome
between the groups can be attributed to the
intervention. If randomisation is not possible, then
baseline differences need to be adjusted for
statistically but systematic differences cannot be
entirely ruled out. 
There are two problems that may arise in
controlled trials:
1. The intervention is inadvertently received by
members of the non-intervention or control
group. This is called contamination.
2. The intervention is not received by members 
of the intervention group. This is called 
non-adherence (or non-adherence or 
non-concordance).
These two problems are similar to each other.
Both tend to blur the distinction between the two
groups. However, they are different processes.
Whereas non-adherence is a potential problem in
most kinds of trials, contamination is thought to
be a particular problem in trials of educational
interventions because of their transferability. That
is, the active ingredients may be difficult to
confine to the subjects for whom they are
intended. For example, a patient who receives
information about risks of obesity can pass that
information on to others. 
Effects of contamination on the
magnitude and statistical
significance (or precision) of the
estimated effect
Contamination will only affect the results of a trial
if the intervention is effective. Contamination of
members of the non-intervention group will tend
to shift the outcome in the control group in the
same direction as the effect in the intervention
group. Hence the effectiveness of the intervention,
estimated as the ratio or difference between
intervention and control groups, will tend to be
underestimated. Thus contamination biases trial
results towards the null – that is, towards a
difference of zero or a ratio of one. For example, if
half of the control group was contaminated, we
might expect the control group overall to
experience half of the effect experienced by the
intervention group.
Another adverse effect of contamination is the
reduction in statistical power to detect a significant
effect, because contamination reduces the
estimated effect of an intervention. This is also
seen as wider confidence intervals (CIs) around
the effect estimate, that is, as decreased precision.
This may lead to the conclusion that the
intervention does not have a significant effect,
when the true effect would have been significantly
different from zero. This means failing to reject
the hypothesis that there is no significant
difference between groups, when that hypothesis is
false (Type II error). Similarly, in an equivalence
trial contamination reduces one’s confidence that
different interventions have equivalent effects.
Figure 1 shows how, with larger cluster sizes,
contamination can severely reduce the power of
trials to show significant effects. Figure 2 shows
how contamination leads to requirements for
larger sample sizes, and more so with greater
intracluster correlation. These figures were
calculated with equations from Donner and Klar.1
Mechanisms of contamination
with different types of educational
intervention
The way in which contamination occurs may differ
according to the educational mechanisms and the
targets of the intervention. The target of the
intervention might be a patient, a healthcare
professional or members of the general public.
Mechanisms, or processes, of contamination in
such trials are discussed briefly here. A wider
range of contamination processes are listed in
Chapter 3.
Health Technology Assessment 2007; Vol. 11: No. 43
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FIGURE 2 Number of clusters needed with increasing degrees of contamination and intracluster correlation coefficients and different
cluster sizes. Increasing degrees of contamination are represented by increasing control means. Total variance is between- plus within-
cluster variance. Continued overleaf.Interventions aimed at patients
Interventions aimed at patients vary in their
complexity and in their desirability. For example, a
patient might receive a leaflet in the mail simply
reminding them that a particular screening test is
due. A more complex intervention might be a
video informing them of how obesity affects health
risks and how to lose weight. An even more
complex intervention might involve the patient
attending a series of motivational interviewing
sessions aimed at helping the patient stop
smoking. Contamination would occur if control
patients were exposed to the intervention, by
reading the leaflet, watching the video or attending
the motivational interviewing sessions. However,
contamination with complex interventions with
many ingredients would tend to have a lesser effect
in control patients than in intervention patients
because the ‘dose’ of exposure would tend to be
less in controls, since the whole intervention
package would be difficult to transfer. 
Interventions aimed at health
professionals
Educational interventions aimed at health
professionals can vary in complexity. Such
interventions include written information, patient-
specific reminders, clinical practice guidelines and
in-depth training courses. Contamination would
occur if some educational content were passed on
to control subjects, either by disseminating the
educational materials themselves or through
mixing between professionals in intervention and
control groups. Contamination would be especially
likely if patients were allocated to intervention and
control groups and the same health professionals
treated patients from both groups. For example,
the intervention could be a patient-specific
reminder to doctors about elderly patients’ need
for influenza vaccination. When intervention
patients visit their doctor, the doctor receives the
reminder, but when control patients visit their
doctor, the doctor does not. It would then be likely
that the way in which the doctor treats control
patients would be affected by the reminders about
intervention patients. 
Interventions aimed at the general
public
Some education interventions are targeted at the
general public. For example, health education
broadcasts, such as a series of short smoking
cessation programmes on local county radio,
might be used as a general public intervention to
particular counties. An alternative or no broadcast
can be aimed at different counties for comparison.
Contamination can occur since the broadcast
reaches other counties.
Avoiding contamination in trials of
educational interventions
Different methods and practices have been
proposed to help avoid contamination. These
methods and practices impact on the design of the
trial and the analysis of the results.
A simple method to avoid contamination is to
educate or instruct the trial participants to avoid
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FIGURE 2 (cont’d)contamination. Patients receiving an intervention
can be asked not to share information with other
patients. Similarly, health professionals can be
requested not to discuss the intervention with
colleagues who might be involved in a different
arm of the trial. Education with regard to general
public interventions may be more difficult because
personal contact with the trial subjects is unlikely. 
Trials designs that avoid contamination
Another method to avoid contamination is to
separate intervention and non-intervention groups
geographically by randomising groups of subjects
rather than individual subjects. For example,
patients who attend the same GP surgery will tend
to have similar social networks and to live near to
one another. This is likely to lead to
contamination if both intervention and non-
intervention patients are selected from the same
GP surgeries. Similarly, health professionals
working in the same institution are likely to meet
regularly. By administering the intervention arm
of the trial at some sites and administering the
non-intervention arm at other sites, it is less likely
that the two groups will meet and discuss the
intervention or share intervention materials, thus
decreasing the likelihood of contamination.
Similarly, with interventions aimed at the general
public, it is wise to choose intervention and non-
intervention groups that are distant from each
other. 
Trials that allocate groups of subjects who share a
geographical location, place of treatment or
health professional to intervention and control
groups are known as cluster randomised trials.1
Cluster randomised trials have the advantage of
reducing the risk of contamination, but they have
statistical disadvantages, compared with
individually randomised trials, because
randomisation information on subjects within
clusters cannot be assumed to be independent of
each other. Therefore, cluster randomised trials
require that a statistical adjustment be made
according to the correlation of outcomes between
members of that cluster. Furthermore, many
clusters are needed to ensure that the groups
being compared are in fact comparable at
baseline. For both reasons, a cluster randomised
trial tends to require a larger sample size to detect
a significant effect with a given power and without
confounding, compared to an individually
randomised trial. Therefore, it has been argued
that in many circumstances individual
randomisation should be used instead of cluster
randomisation. The greater power of the
individually randomised trial would outweigh the
loss of power caused by contamination, especially
where the risk of contamination is low and where
outcomes are highly clustered.2,3 However, this
argument leaves aside the separate problem of
biased effect estimation. Contamination leads to
an underestimate of the magnitude of effect of the
intervention, but cluster randomised trials may be
confounded if the number of clusters is small.
Such bias or confounding may mislead decisions
about whether or not the intervention is
worthwhile. The trade-offs between cluster and
individually randomised trials therefore involve
both bias and power.
The Zelen design entails randomising patients
before asking for their consent to participate in a
trial.4 Consent can be elicited in one of two ways,
namely the single consent design and the double
consent design. The single consent design first
randomises subjects to the control or intervention
arm of the trial. Those randomised to the
intervention group are then asked to consent to
the intervention. Subjects who refuse consent to
the intervention receive the control treatment.
Those randomised into the control arm are not
asked to consent to receiving the control treatment
because this is what they would be receiving
anyway. This method avoids disappointing those
who may have liked to receive the intervention but
are allocated not to, which could affect their
behaviour or their reporting of outcomes. By
reducing control subjects’ awareness of the
intervention, it also reduces the likelihood that
control patients seek the intervention for
themselves. All subjects are included in the
analysis in the groups to which they were allocated
[an intention-to-treat (ITT) analysis], regardless of
their consent. This design may therefore help to
avoid contamination of the control group, by not
informing them of the alternative intervention,
but it would cause non-adherence in the
intervention group if many of those allocated to
receive the intervention choose not to do so.
Furthermore, it may be unethical to include
control patients in a trial without their consent. 
The double consent Zelen design is similar, except
that the control group are asked for consent to
receive the control treatment. If they refuse, they
are offered an alternative treatment, which may be
the experimental intervention. This design
ensures that subjects are in agreement with the
intervention that they receive. However, as with
the single consent Zelen design, a dilution bias
can be introduced if a large number of subjects
cross over to an intervention contrary to the
original randomisation.
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contamination 
It is possible to adjust for contamination when
analysing the results of a trial. A simple method of
adjustment where participants are known to be
contaminated is to categorise contaminated
control members as belonging to the intervention
arm, and thus to analyse them as intervention
subjects (per protocol analysis). The main problem
with this is that one can no longer assume that
randomisation has made the groups being
compared the same on average. Furthermore, the
intervention received via contamination cannot be
assumed to be equivalent to the full intervention.
Alternative methods that retain the advantage of
randomisation are discussed in Chapter 5. General
statistical methods for adjusting for confounding
in epidemiological studies can also be used to
adjust for contamination. A confounding variable
is one that is associated with the exposure (that is,
is more or less likely in intervention than in
control groups) and is also associated with the
outcome. This is particularly a problem with non-
randomised controlled trials (RCTs), in which
statistical adjustment for confounding is usually
necessary. For example, in a trial of nutritional
advice, if control group subjects had less healthy
diets than intervention group patients before the
trial started, the effect of the intervention could be
overestimated. Such a confounding factor would
need to be adjusted for in the analysis to increase
the validity of the effect estimate. Multiple
regression methods are usually used to adjust for
several confounding variables. Stratified analysis,
for example using Mantel Haenzel tests, is an
alternative. In controlled trials, this may be
necessary if there is poor comparability between
exposed and unexposed groups. 
Propensity score matching is also used to adjust
for confounding or selection bias. Factors that are
associated with patients being in one or another
arm of the trial are identified, and used to predict
the probability that each subject will be allocated
to one arm or another. This probability should be
0.5 in a randomised trial with equal sized arms.
Propensity scores can be used to adjust for these
systematic differences in subjects’ characteristics in
various ways. There is evidence that adjusting for
propensity scores is a better way to adjust for
systematic differences in patients in each trial arm
than adjustment for confounders.5
The main disadvantage of adjusting for baseline
differences in randomised trials is that it
undermines the fundamental assumption that the
two arms are on average the same in all
characteristics, including those that have not been
measured, and that any baseline differences must
have occurred by chance. Thus it may undermine
the comparability of groups.
Definition of contamination
In this study, we define contamination to be the
process whereby an intervention intended for
members of the trial (intervention or treatment)
arm of a study is received by members of
another (control) arm.
This process could be simple and immediate or it
could be complex and slow. It could occur both
ways at once, so that some members of each group
receive some of the intervention intended only for
the other group. However, contamination is
assumed to occur if at least some members of the
control group receive at least some of the
intervention.
Outline of the study
Our approach to this challenge has four distinct
elements. 
Review of the literature
To provide an empirical evidence base, we
investigated the extent to which contamination has
been reported in trials of educational
interventions. Preliminary bibliographic searches
identified little direct evidence of the degree of
contamination and its effect in reports of
educational trials. We therefore looked for indirect
evidence of contamination examined in exemplar
systematic reviews of trials of educational
interventions by comparing effect estimates
between trials in which contamination was more or
less likely. We report in more detail on one trial
which allowed comparison of the design effects of
cluster and individually randomised trials. 
Eliciting expert opinion 
A two-stage Delphi questionnaire, together with a
pilot study issued to members of the project team,
was used to elicit a consensus of expert opinion on
the extent to which different factors are likely to
influence contamination and the most appropriate
methods of avoiding it.
Simulating the mechanisms and effects
of contamination over time
In order to investigate the effect of contamination
Introduction
6according to key parameters such as the efficacy,
desirability or transferability of the intervention, a
computer simulation was carried out. The
simulation model was written for both cluster and
individual randomisation and the two designs
were compared. 
Statistical adjustment for contamination
with Complier Average Causal Effect
and instrumental variable analysis 
We used published examples of trials in which
contamination or non-adherence was known to
have occurred, to show how to adjust for
contamination, with aggregated results, using the
Complier Average Causal Effect (CACE) method.
We then simulated individual level data to show
how, if contamination is known to have occurred,
it can be adjusted for using instrumental variable
regression methods. 
We conclude by bringing these various elements of
the project together to provide an overview of
when contamination is likely or unlikely and how
best to avoid it.
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and quantify evidence of, type and cause of
contamination in existing research. The search
comprised a review of journal articles identified by
searching bibliographic databases and
handsearching selected journals, and secondary
analyses of systematic reviews of exemplar
educational interventions. This was an exploratory
search. A systematic review of all potentially
relevant evidence was beyond the scope of this
study because of the wide range of types of
educational interventions that were covered.
Finally, we report in more detail on a randomised
trial within a randomised trial that compared
effects estimated by cluster randomisation with
effects estimated by individual randomisation. 
Direct evidence of contamination
reported in trials of educational
interventions
In order to locate relevant studies, whether
methodological studies or trials, in which
contamination was reported, two database searches
were performed and updated in May 2005. First, a
MEDLINE search on the terms ‘contamination’
and ‘trial’ was performed. This identified 689
papers. The documents retrieved via this search
method tended either to fall into the category of
microbiological contamination or used the term
‘contamination’ as part of a justification for a
cluster randomised trial rather than to provide
any evidence about contamination. Five of the
papers reported either the degree of
contamination or methods to estimate the effect of
contamination.
Second, the Web of Science database was searched
using the same criteria; 274 papers were retrieved
by this search, five of which reported the degree of
or methods to estimate contamination. Four of
these studies overlapped with the MEDLINE
search.
Third, we performed a handsearch of the
following journals:
● Health Education, 2000 and 2001 
● Medical Education, 2004
● American Journal of Health Promotion, 2003 and
2004
● Education for Health: Change in Training and
Practice, 1998–2001. 
Trials in which extent of contamination
was reported
Eight studies clearly stated that contamination had
occurred and quantified the extent of
contamination (Table 1).
Labarre and colleagues6 conducted a controlled
trial of physical education in schools in which
intervention and control groups were selected
from different age cohorts. They assessed
contamination but found none. They speculated
that this was because pupils of different ages tend
not to play together.
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Chapter 2
Literature search
TABLE 1 Summary of contamination quantities in published literature
Reference Intervention Contaminationa (%)
Labarre et al., 19946 Physical education 0
Courneya et al., 20037 Moderate intensity exercise 22
Courneya et al., 20048 Home-based exercise 52
Courneya et al., 20039 Home-based exercise 52
Ross et al., 200410 Multiple media 65
Goel et al., 199811 Mammography screening 17
Tilgren et al., 199812 In-home health education 40/25/2.6b
Stewart-Brown et al., 200413 Parenting training 10
a Percentage of control patients who were exposed to the intervention.
b Three different types of contamination reported.Courneya and colleagues9 describe a randomised
trial to evaluate enhanced quality of life in cancer
survivors by comparing GP group psychotherapy
with GP group psychotherapy plus moderate
intensity exercise; 22% of control subjects received
the intervention.
Courneya and and colleagues7 measured adherence
by the intervention group and contamination in
the control group in a different randomised trial
to determine effects of home-based exercise
intervention on change of quality of life in
recently resected colorectal cancer survivors; 52%
of the control group and 76% of the intervention
group were exposed to the intervention.
In another study, Courneya and and colleagues8
conducted a trial to examine predictors of
adherence and contamination in an RCT of a
home-based exercise intervention for colorectal
cancer survivors. The trial results suggest that
contamination in the control group was 52% and
adherence in the intervention group was 76%.
Regression analysis showed that subjects’ intentions
( = 0.35, p = 0.001) and stages of change ( =
0.35, p = 0.095) regarding exercise at baseline
explained 30% of the variance in contamination.
Ross and colleagues10 presented evidence of
contamination in a community-level syphilis
intervention trial using several media, namely
brochures and posters, coasters, matchbooks, T-
shirts, videos and billboards containing slogans
and logos. Control members were exposed to an
average of 2.04 intervention items whereas
intervention members were exposed to an average
of 2.99 items; 65% of the control group were
exposed to at least one of the intervention media
(contamination), compared with 71% of the
intervention group (adherence).
Goel and and colleagues11 estimated
contamination in a trial of mammography
screening by using insurance billing records to
identify women who sought a non-screening
mammogram outside the screening trial. The trial
found that, for women aged 40–49 years, 2.2% in
the intervention group and 14.1% in the control
group had a claim for at least one bilateral
mammogram, indicating adherence and
contamination respectively. In the age group
50–59 years, 4.5% in the intervention group and
16.7% in the control group were exposed. 
Tilgren and colleagues12 conducted a study to
assess the prevalence and intensity of
contamination in a community-based trial of
education about cervical cancer screening. The
trial used individual randomisation and had two
control groups. The intervention was conducted in
the homes of subjects by lay health educators. Pre-
test surveys were conducted in one of the control
groups and post-test surveys in both control
groups. Of the 185 control subjects who were
interviewed, 40% were aware of the programme,
25% knew that the programme concerned cervical
cancer and three had specific knowledge of the
content or had seen the educational materials.
Stewart-Brown and colleagues13 conducted a study
to analyse the effectiveness of a parenting
programme on a sample of parents of children
whose behaviour was worse than average. A total of
116 parents were randomised into control and
intervention groups; 23 intervention arm parents
and 15 control arm parents were interviewed about
their approach to, and difficulties with, parenting.
Intervention parents were asked their opinion of
the intervention. The intervention targeted
behaviour and used videotape modelling and
experiential learning including child play, praise
and rewards. A significant change (p < 0.05) in a
positive direction was observed for the intervention
group at 12 months using the Eyberg inventory. A
total of 31 of 60 parents in the intervention group
attended 50% or more sessions. Control parents
showed significant improvements on all scales of
the parenting stress index and intervention
patients showed significant improvements on all
parenting stress index measurements except
parent–child interaction. Control parents indicated
that the questionnaires had encouraged them to
reflect on their parenting and four of 41 control
parents indicated that they had attended a
parenting programme before 12-month follow-up
(10% contamination); also one non-attender from
the intervention group attended a parenting
programme within 12 months.
In summary, these studies show how different
types of contamination may occur in trials of
different types of educational intervention.
However, they do not provide evidence of how
much contamination affected the statistical
significance and validity of their results.
Indirect evidence of contamination
among a diverse group of trials of
educational interventions aimed at
health professionals
In order to obtain a relevant source of data of
trials of educational intervention in which to study
Literature search
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review, by Grimshaw and colleagues.14 This
reviewed 235 studies of educational interventions
together with financial and strategic interventions.
The investigators had categorised each study in
terms of its potential for contamination as
‘contamination avoidance done’ (D),
‘contamination avoidance not clear’ (NC) 
and ‘contamination avoidance not done’ (ND).
‘Contamination avoidance done’ usually meant
that a cluster randomised trial design was used.
We analysed separately the following subsets of
these studies:
1. All studies.
2. A subset of relatively homogeneous studies.
Each study evaluated an intervention which
used some type of reminder (to receive
vaccination or screening) compared with a
control group that received nothing.
3. A subset of item 2 that met at least one study
quality criterion.
For each analysis we aimed to test the prior
hypothesis that, for the wide range of educational
interventions evaluated, effects would tend to be
greater in trials that avoided contamination by
cluster randomisation compared with trials that
were individually randomised.
All studies analysis
Methods
The Grimshaw review data for 158 studies from
201 papers15–215 were analysed, using the
following variables reported for each study. The
study designs included both cluster and non-
cluster RCTs and controlled before–after studies: 
1. Trial design (individual or cluster allocation to
comparison groups).
2. Targeted behaviour (test ordering, prescribing,
prevention or patient education).
3. Type of intervention (educational materials,
educational meetings, reminders, audit and
feedback or financial interventions).
4. Educational outcomes in control and
intervention groups.
5. Difference in outcome between control and
intervention groups.
6. Reviewers’ classification of contamination
avoidance:
(a) Done: cluster allocation by community,
institution or practice and unlikely that
control group received the intervention.
(b) Not clear: professionals allocated within a
clinic or practice and possible that
communication between experimental and
control group professionals could have
occurred.
(c) Not done: likely that control group
received the intervention, for example
cross-over trials or if patients rather than
professionals were randomised.
We compared outcomes in intervention and
control groups using L’Abbé plots, as follows.
These plots are explained in a paper by L’Abbé
and colleagues216 and used by Song.217
1. Each study from the Grimshaw review was
plotted as a coordinate point on the plot with
reference [intervention arm effect (%), control
arm effect (%)].
2. A line representing control = intervention was
plotted
3. The shortest distance from each coordinate
point to the control = intervention line was
calculated (the shortest distance will meet the
control = intervention line at a right-angle). If
the effect of the intervention is the same as the
control, the mean L’Abbé distance will be zero.
Otherwise, the distance represents the
improvement or otherwise as a result of the
intervention.
4. Also included was a line of best fit passing
through the origin, calculated by linear
regression, and summarising the tendency of
the data.
To maximise the sample size, we initially
examined all trials, regardless of their design, and
compared them according to their contamination
classification. The L’Abbé plots for the three types
of trial are shown in Figures 3–5.
Results
The results of this preliminary analysis were the
opposite of what we had hypothesised. We would
expect contamination to decrease the L’Abbé
distance since it would bias the control outcome in
the direction of the intervention outcome.
However, Table 2 and Figure 3 show that the trials
classified as ‘contamination avoided’ have the
smallest distances from the control = intervention
line and therefore have the smallest difference
between control and intervention effect. The trials
with contamination avoidance not clear or not
avoided have larger differences, with
contamination not avoided trials having the
largest difference between control and
intervention effect. 
Summary statistics for the distances from each
point to the control = intervention line are given
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box plots in Figure 6.
There are several possible explanations for this
finding. First, the trials were very heterogeneous,
so the above comparisons could be invalid.
Second, in some trials the interventions may have
had a negative, although beneficial, effect (a type
of heterogeneity). Third, cluster randomisation
may have been used more often in situations
where contamination was most likely, but did not
eliminate it. Fourth, researchers who were
experienced enough to know where cluster
randomisation was appropriate may also have
been better at avoiding other sources of bias. Fifth,
most trials were small, so publication bias could
have resulted from those with larger effects being
more likely to be published. In summary,
therefore, the above results should be interpreted
cautiously.
To test the second of these explanations (whether
these results had been biased by inclusion of trials
with a negative direction of intervention effect), we
repeated the analysis, first excluding studies with a
negative direction of effect [leaving 82 trials with
contamination avoidance done (the corresponding
papers with contamination avoidance done and
positive effect are Refs 15–19, 21, 25, 26, 28, 33,
38, 44, 52, 54, 55, 57–61, 65, 66, 68–74, 75, 81,
82, 85, 87–89, 93–99, 108–113, 118, 119, 122,
127, 128, 132–134, 137, 142–144, 148, 152, 153,
154, 160, 162, 175, 177, 181, 184, 185, 195–197,
201, 202, 211, 212), 65 not clear (the
corresponding papers with contamination
avoidance not clear and positive effect are Refs 20,
22, 24, 29, 30, 32, 43, 45, 46-50, 53, 56, 62–64,
67, 78, 80, 83, 106, 114, 115, 120, 121, 123, 129,
139, 140, 145, 147, 156, 161, 172–174, 178, 179,
183, 187, 192–194, 208, 210, 215, 216) and 
39 not done (the corresponding papers with
contamination avoidance not done and 
positive effect are Refs 27, 31, 35, 37, 39, 40, 
42, 75, 84, 90, 91, 100, 101–104, 107, 125, 
126, 136, 138, 155, 163, 167, 182, 188, 190, 
191, 198, 203–207, 209)] and second excluding
studies with a positive direction of effect 
(leaving 1115,34,86,116,117,135,158,159,166,211,213
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FIGURE 4 Rate ratio fit: all trials, contamination avoidance not
cleartrials with contamination avoidance done,
1532,41,43,51,67,77,79,124,141,146,157,176,183 not clear and
three31,92,105 not done) (some trials in the
Grimshaw review quoted more than one result; it
is therefore possible for a study to feature in both
positive and negative effect categories).
For trials where the effect of the intervention is
expected to be positive, the distances measured by
the L’Abbé plot are summarised in Table 2 and
displayed in the L’Abbé plots in Figures 7–9 and as
box plots in Figure 10.
These results show that, for positive effect
interventions, ‘contamination avoidance done’
trials still had smaller effects than the other 
trials. However, the ‘contamination avoidance not
clear’ trials show a slightly larger mean effect size
than the ‘contamination avoidance not done’
trials.
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TABLE 2 Summary statistics for L’Abbé distances
All studies
Minimum  1st quartile Median Mean  3rd quartile Maximum
Contamination avoided 0  1.414  4.384  6.631  9.192  48.08
Contamination avoidance not clear 0.2121 2.616  6.081 9.848  14.14  57.28
Contamination not avoided 0 2.121  7.354 9.259  13.26  38.18
Studies with positive direction of effect
Contamination avoidance done 0 1.573 4.95 7.284 9.458 48.08
Contamination avoidance not clear 0.2121 3.323 6.364 10.77 14.85 57.28
Contamination not avoided 0 3.359 8.485 9.908 13.44 38.18
Studies with negative direction of effect
Contamination avoidance done 0.354 0.746 1.414 1.763 2.475 3.96
Contamination avoidance not clear 0.354 0.530 0.707 0.825 1.061 1.414
Contamination not avoided 0.212 0.707 1.909 5.864 6.116 42.43
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FIGURE 6 Box plots of L’Abbé differences for all studies reviewed by Grimshaw and colleagues14We then excluded the interventions with positive
effects and studied only those whose effectiveness
decreased the measure of effect. The L’Abbé
differences for studies with negative direction of
effect are summarised in Table 2. The L’Abbé plots
are shown in Figures 11–13 and box plots of these
differences are shown in Figure 14.
As the table and plots show, studies with negative
effects agree with the hypothesis that avoiding
contamination increases the effect size. However,
the sample sizes are very small and so these
findings could be due to chance.
Subset of higher quality studies
It is possible that the quality of the study will
influence the effect of contamination since 
poor-quality trial results may be biased by factors
other than contamination. We therefore examined
only studies that met at least one quality criterion
used in the Grimshaw review, namely
randomisation concealed, outcome assessment
blind, outcomes reliable and baseline
measurements comparable. An analysis of the
positive effect studies of this type follows.
L’Abbé plots are shown in Figures 15–17 and 
the L’Abbé distances for these plots are
summarised in Table 3.
A graphical representation of these L’Abbé
distances is shown in Figure 18. The results 
suggest that the differences between control 
and intervention results are greater for trials
where contamination was not avoided. This 
result is contrary to the hypothesis that
contamination reduces the estimate of 
effect.
This preliminary analysis yielded no evidence 
to suggest that contamination biases the estimated
efficacy of educational interventions. However,
because of the variety of types of intervention and
aim of the trials, it is possible that the above
comparison is one of qualitatively different trials.
We therefore performed a further, more detailed
analysis of a more homogeneous set of
interventions.
Literature search
14
0
20
40
60
80
100
I
n
t
e
r
v
e
n
t
i
o
n
0 20 40 60 80 100
Control
* *
*
*
**
*
*
*
* *
*
* *
*
**
*
*
*
** *
*** *
* **
*
* * ** * * * * * *
*
** *
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
* **
* *
* *
* **
*
* *
***
*
**
**
*
FIGURE 7 Positive effects trials, rate ratio fit: contamination
avoided
0
20
40
60
80
100
0 20 40 60 80 100
Control
*
**
**
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
* ** *
*
*
*
*
*
*
** *
* *
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
**
* * *
*
*
*
**
* *
**
I
n
t
e
r
v
e
n
t
i
o
n
FIGURE 9 Positive effect trials, rate ratio fit: contamination not
avoided
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FIGURE 8 Positive effect trials, rate ratio fit: contamination
avoidance not clearIndirect evidence of
contamination among a
homogeneous group of trials of
educational interventions aimed
at health professionals
We then analysed a set of similar studies to test the
hypothesis that the differences attributable to
contamination between these studies would
become clearer. This was a subset of the studies
reviewed by Grimshaw and colleagues.14 They all
evaluated a reminder intervention, in which
professionals were reminded about appropriate
ways of managing particular patients. It includes
38 studies published between 46 research papers.
The types of reminder vary from pop-up messages
on a doctor’s computer to the completion of
patient encounter forms and letters to patients.
The subjects of the intervention vary between
Health Technology Assessment 2007; Vol. 11: No. 43
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FIGURE 11 Negative effect trials, rate ratio fit: contamination
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FIGURE 10 Box plots of L’Abbé differences for positive effect studies in Grimshaw and colleagues14physician, health professional and patient, and 
the duration of studies varies from weeks to 
years.
A summary of the L’Abbé differences for these
homogeneous studies is given in Table 4. 
However, there were just two studies81,127,128
classified as contamination avoided,
1829,43,45,50,51,106,107,114,146,172,174,179 classified as not
clear and 1727,40,84,92,125,126,136,167,190,203,207
classified as not done.
These differences are further summarised in
Figures 19–21 and box plots are shown in 
Figure 22.
Although the sample size for contamination
avoided studies is small, the above box plot is an
illustration of the behaviour that might be
expected if contamination reduces effect size.
For the majority of homogeneous studies, we have
access to the study sample size. For contamination
Literature search
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FIGURE 14 Box plots of L’Abbé differences for negative effect studies in Grimshaw and colleagues14Health Technology Assessment 2007; Vol. 11: No. 43
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FIGURE 16 L’Abbé plot for all high-quality studies with positive
effect, rate ratio fit: contamination not avoided
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FIGURE 17 L’Abbé plot for all high-quality studies with positive
effect, rate ratio fit: contamination avoidance not clear
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FIGURE 18 Box plots of L’Abbé distances for all high-quality positive effect studies in Grimshaw and colleagues14
TABLE 3 Summary of L’Abbé distances for all high-quality positive effect studies
Minimum  1st quartile Median Mean  3rd quartile Maximum
Contamination avoideda 0 1.414 4.419 5.406 7.973 23.330
Contamination avoidance not clearb 0.424 4.243 8.485 11.950 17.960 38.180
Contamination not avoidedc 0.212 2.333 4.243 7.781 11.140 57.280
a This group consisted of 52 studies from Refs 15, 21, 25, 26, 28, 38, 44, 54, 55, 65, 68–72, 75, 81, 82, 85, 89, 93–96, 98,
108, 110, 111, 116, 117, 122, 132–134, 137, 142, 144, 148–151, 160, 162, 175, 177, 180, 181, 184–186, 195–197, 201,
202, 212.
b The contamination avoidance not clear group here consisted of 41 studies from the Refs 20, 22, 24, 29, 32, 43, 50, 62, 63,
80, 114, 115, 121, 123, 129, 139, 140, 145, 156, 161, 172–174, 178, 179, 190, 187, 193, 194, 210, 215.
c The contamination not avoided group here consisted of 21 studies from the Refs 31, 35, 39, 42, 76, 84, 100, 104, 125,
138, 163, 165, 167, 171, 191, 198, 209.avoided studies, the mean sample size is 64.5 
and for studies where contamination was not
avoided, the mean sample size is 451.3; both
datasets have very large variance and a simple test
of mean difference between the samples shows no
evidence to suggest equality of the means
(p = 0.21).
Subset of higher quality studies
In addition to the analysis of data from the
perspective of contamination likelihood, it 
was also decided to examine the data from the
point of view of study quality. By removing low-
quality studies from our analysis, we intended to
obtain a set of studies that were both
homogeneous in nature and with valid effect
estimates. 
Methods
We included studies that met at least one study
quality criterion, that is, randomisation
concealment, blinded assessment and baseline
measurement comparability This further reduced
the sample size. In order to make use of all
studies, we omitted the classification
‘contamination avoidance not clear’ and divided
the studies into individually randomised and
cluster randomised trials (since individually
randomised trials are more likely to be
contaminated).
Literature search
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TABLE 4 Summary of L’Abbé distances for homogeneous studies in Grimshaw and colleagues14
Minimum  1st quartile Median Mean  3rd quartile Maximum
Contamination avoided 14.14 16.44 18.74 18.74 21.04 23.33
Contamination avoidance not clear 0 0.808 2.687 4.674 7.707 14.71
Contamination not avoided 0.566 1.414 8.485 8.507 13.440 28.28
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FIGURE 20 Homogeneous studies, rate ratio fit: contamination
avoidance not clearResults
We performed L’Abbé plot analysis on the high-
quality individually randomised and high-quality
cluster randomised study results. Sample sizes
were very small with just six27,40,92,126,190,203
individual and five43,114,167–171,179 cluster studies.
L’Abbé plots for this analysis are shown in
Figures 23 and 24.
Bearing in mind the small sample sizes, the fitted
lines in the plots suggest that the cluster
randomised trial results are further from the
control = intervention line with two points close to
control = intervention. The individually
randomised trials have four points close to the
control = intervention line and two studies with a
larger effect. Summaries of these differences are
given in Table 5.
These results show that the L’Abbé distances for
the high-quality cluster randomised studies are
larger for first quartile, median, mean and third
Health Technology Assessment 2007; Vol. 11: No. 43
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FIGURE 23 Rate ratio fit: individually randomised high-quality
studies
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FIGURE 24 Rate ratio fit: cluster randomised high-quality
studies
FIGURE 22 Box plots for L’Abbé distances for homogeneous studies in Grimshaw and colleagues14
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These results are further illustrated in the box
plots in Figure 25.
Although the sample size for this analysis is too
small to enable us to make a confident inference,
the results are in keeping with the suggestion that
studies avoiding contamination tend to have larger
effect size.
Indirect evidence of
contamination among a
homogeneous group of trials of
educational interventions aimed
at patients
We examined trials evaluating smoking cessation
interventions based on the stages of change
approach and reviewed in Riemsma and
colleagues.218 This exemplifies trials of a range 
of related interventions aiming to change patient
attitudes or behaviour likely to affect their 
health. 
Stages of change analysis
Our second group of homogeneous papers for
analysis were those published in the stages of
change review by Riemsma and colleagues.218 We
examined 13 homogeneous studies of smoking
cessation interventions reviewed in that
report.219–231 Of these studies, 10219–228 reported
results in such a way that the results could be
extracted and compared. The interventions used
in these studies varied, but most considered the
stages of smoking cessation pre-contemplation,
contemplation and action. Other results included
quit rates of various durations and over various
intervals of time. The main problem with some of
the results reported in these studies was that very
few of the interventions reviewed resulted in a
significant absolute quit rate, which makes
estimation of the amount of contamination
difficult (since if there is no effect, there can be no
contamination effect).
Aim
As with our analysis of Grimshaw and 
colleagues’ review,14 it was our intention to
compare the results of the smoking cessation
Literature search
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TABLE 5 Summary of L’Abbé distances for high-quality homogeneous studies in Grimshaw and colleagues14
Minimum  1st quartile Median Mean  3rd quartile Maximum
Individually randomised 1.414 2.422 3.783 8.768 14.690 23.330
Cluster randomised 0.7071 3.818 11.6 9.758 14.71 17.96
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FIGURE 25 Box plots for L’Abbé distances for cluster and individually randomised studiesstudies and examine the effect, if any, that
contamination has on the measured intervention
effect.
Method
Having obtained the original papers for the
13 smoking cessation studies, we sought to identify
results that could be compared between studies
(such as quit rate percentages), and classified
studies according to their potential for
contamination. Trials where the intervention and
control arms were clustered to geographically
separate trial arms were classified as having low
likelihood of contamination. Trials where the 
trial design was likely to lead to contamination
(such as the same doctor administering different
arms of the trial) were classified as highly likely to
lead to contamination, even where the
intervention was difficult to transfer. Results where
the intervention was less effective than the control
were ignored. Some studies asserted that
contamination occurred during the trial and these
were classified as having high likelihood of
contamination.
Results
The L’Abbé plots in Figures 26 and 27 show the
results for high and low contamination likelihood
studies.
The fitted line in Figure 27 for studies with low
likelihood of contamination suggests a larger
general effect size than for the studies with high
likelihood of contamination. In fact, the points
representing the control and intervention effects
are evenly scattered around the control =
intervention line, suggesting a similar effect in
both arms of the trial. This could be attributable
to an ineffective intervention, but could equally be
attributed to contamination, especially in view of
the fact that some of the trial results in Figure 26
are known to be contaminated.
Summaries of the L’Abbé distances are given in
Table 6. These distances are also plotted in the box
plots in Figure 28.
The results suggest that the contaminated trials
have a smaller effect than the trials that are
Health Technology Assessment 2007; Vol. 11: No. 43
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FIGURE 26 Rate ratio fit: interventions with high likelihood of
contamination
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FIGURE 27 Rate ratio fit: interventions with low likelihood of
contamination
TABLE 6 L’Abbé distance summary for homogeneous smoking cessation studies
Minimum  1st quartile Median Mean  3rd quartile Maximum
Contamination not likely 1.061 2.563 3.429 5.455 4.95 29.98
Contamination highly likely 0.141 0.583 1.732 2.726 4.685 8.344unlikely to be contaminated. This conclusion is
different from that observed for the Grimshaw
data, but is in agreement with our theoretical
expectations. However, the sample sizes used in
this analysis are small.
Indirect evidence of
contamination in a randomised
trial of an educational
intervention aimed at patients,
comparing design effects of
cluster and individual
randomisation
A study entitled ‘The effectiveness of enhanced
oral health advice and instruction upon patient
oral hygiene, knowledge and self-reported
behaviour: two parallel trials using patient and
cluster randomised controlled designs’ is
particularly relevant to the comparison of cluster
or individually randomised trial designs. This
study has been submitted for publication
elsewhere and is included in this section by kind
permission of the Vocational Dental Practitioners
Trials Group (C Ramsay, University of Aberdeen:
personal communication, 2005). We provide here
an overview of the trial focusing on the evidence
that it provides about contamination bias in cluster
compared with individually controlled trials. 
Introduction
Increasing emphasis is now being placed by
patients, professionals and policy makers on the
need for the provision of preventive care within
the General Dental Service. A priority is the
provision of effective oral health advice to dental
patients. Studies show that current methods of
delivering oral hygiene advice have varying
success in influencing patient oral hygiene but the
quality of the studies has been mixed. This study
aimed to evaluate the effectiveness of providing
oral health advice and instruction, in general
dental practice, on the oral hygiene, cognitions
and self-reported behaviour of adults. In addition,
to provide information on whether a cluster or
individual randomisation should be the preferred
design of future practice-based oral health advice
studies, the study investigated contamination
effects by simultaneously conducting an
individually and a cluster randomised trial.
Methods
Two trials of the same intervention were
conducted in parallel. One trial used an
individually randomised controlled design. The
other trial used a cluster (dentist) randomised
controlled design. Apart from the method of
allocation, all procedures in each trial were
identical.
Participants
Eligible dentists were those who were spending
their vocational training year in Scotland. Eligible
patients were dentate adults who had already
made an appointment for a routine check-up.
Intervention
The intervention was an evidence-based package
consisting of a powered toothbrush and oral
hygiene advice. The content and delivery of the
advice were framed to influence oral hygiene self-
efficacy. Dentists demonstrated how to brush teeth
using the toothbrush (including giving oral
hygiene advice) and then asked the patient to
Literature search
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FIGURE 28 Box plots of L’Abbé distances for smoking cessation studiesbrush their teeth so that they could see if they
were brushing correctly.
Primary outcome measures
● Clinical – the buccal and lingual aspects of all
margins/surfaces in the upper left and lower
right quadrants were investigated using the
Silness and Loe index to record the amount of
plaque and the presence or absence of bleeding
at the gingival margin on gentle probing.
● Behavioural – self-reported brushing frequency,
duration and rinsing behaviour.
● Cognitive – oral hygiene self-efficacy as
measured by the mean score of five summed
items examining the extent to which patients
felt they could perform oral hygiene-related
behaviours.
Outcomes for both trials were assessed in the
primary care setting by self-completed
questionnaires at baseline and at 8 weeks and by
clinical examination at baseline on all patients,
and at 8 weeks only for patients who required a
further examination.
Sample size
Both trials were powered to detect the same size of
effect [80% power at the 5% significance level to
detect an absolute reduction of 10% in the
proportion of sites with bleeding – 40 to 30%;
standard deviation (SD) of 35%]. The cluster
randomised trial assumed an intracluster
correlation coefficient of 0.05.
Randomisation
All participating dentists were first randomly
selected to the individually or cluster randomised
trial. For the individually randomised trial,
patients were randomised to either the routine
care group or the enhanced oral hygiene care
group according to a practice level block
randomisation sequence. For the cluster
randomised trial, dentists were randomly allocated
to either the routine care group or the enhanced
care group and the patients received the
intervention that the dentist was allocated.
Blinding
All patients were blinded to outcomes assessment
at baseline. Given that the intervention was
allocated by cluster in one of the trials, it was not
possible to blind the dentist to allocation.
Results
Eighty-four dentists (34 in the patient randomised
trial and 50 in the cluster randomised trial) took
part in the study. In total, 799 patients consented
to take part in the study; 310 were recruited to the
patient randomised trial (155 control and 155
intervention) and 489 to the cluster randomised
trial (248 control and 241 intervention). The
mean (SD) number of patients recruited by each
dentist was 8.6 (3.5) and 9.6 (3.1) for the patient
and cluster randomised trials, respectively.
There were no substantive differences in patient
characteristics at baseline between the control and
intervention groups within or between each trial in
demographic, clinical, behavioural or cognitive
outcomes. The average age was approximately
37 years; just over 75% used a manual toothbrush;
approximately one-third of gingival margins were
bleeding; and about half of surfaces had plaque.
All primary cognitive and behavioural outcomes
showed statistically significant positive changes in
both trials (Table 7). For the clinical outcomes, only
the cluster randomised trial demonstrated a
statistically significant reduction in plaque,
although all other clinical outcomes showed a
similar direction of effect (plaque reduction) in
both trials. For three of the primary outcomes, the
magnitude of effect was substantially greater in the
cluster randomised trial than in the individual
randomised trial. 
Measures of possible contamination are given in
Table 8. The use of an electric toothbrush was an
integral part of the intervention and we observed
at follow-up that 8.2% of the patient randomised
trial control group changed to an electric
toothbrush compared with 4.7% in the cluster
randomised trial. There were similar order of
magnitude differences between the control 
groups for the behavioural measures, but the
direction of effect was inconsistent, for example,
the patient randomised trial control group
sometimes showed less increase in knowledge
compared with the cluster randomised trial
control group.
Interpretation
This study, conducted throughout Scotland, was
the first national study investigating the
effectiveness on patient oral hygiene, knowledge
and behaviour, of dentists giving oral health
advice under normal day-to-day dental surgery
conditions. The results of both trials indicated that
self-reported patient oral hygiene behaviour and
cognitions could be successfully influenced in
general dental practice by targeting self-efficacy
expectancies towards toothbrushing. However, the
patient randomised trial and the cluster
randomised trial obtained slightly different results
Health Technology Assessment 2007; Vol. 11: No. 43
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effects to the clinical outcomes. The patient
randomised trial showed no statistically significant
difference between the intervention and control
groups, whereas the cluster randomised trial
showed that the intervention group had more
statistically significant and larger favourable
clinical outcomes than the control group. 
Assessment of contamination, however, suggests
that this apparent difference was not necessarily a
result of contamination. The results in Tables 7
Literature search
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TABLE 7 Primary outcomes
Patient randomised trial Cluster randomised trial
Control Intervention Adjusteda p-Value Control Intervention Adjustedb p-Value
difference difference 
(95% CI) (95% CI)
Primary cognitive measures
Self efficacy N = 117 N = 115 N = 201 N = 165
Baseline – mean (SD) 27.5 (5.3) 27.9 (5.9) 26.7 (5.6) 28.3 (5.1)
N = 17 N = 115 N = 201 N = 165
Follow-up – mean (SD) 26.7 (5.2) 28.3 (5.8) 27.0 (5.3) 28.7 (4.4)
1.5 (0.2 to 2.8) 0.024 0.9 (0.01 to 1.8) 0.047
Primary clinical measures
Percentage surfaces bleeding N = 47 N = 36 N = 80 N = 105
Baseline – mean (SD) 32.4 (25.6) 27.7 (27.7) 34.8 (28.8) 40.4 (27.6)
N = 47 N = 36 N = 80 N = 105
Follow-up – mean (SD) 21.8 (25.4) 15.5 (16.7) 26.0 (26.3) 21.6 (20.6)
–3.5 (–11.8 to 4.8) 0.404 –7.4 (–15.0 to 0.2) 0.057
Percentage surfaces  N = 47 N = 37 N = 80 N = 105
with plaque
Baseline – mean (SD) 52.1 (30.4) 52.5 (27.7) 52.8 (32.4) 46.9 (34.2)
N = 47 N = 37 N = 80 N = 105
Follow-up – mean (SD) 31.2 (23.5) 27.6 (19.8) 54.0 (31.1) 31.2 (26.4)
–4.5 (–12.7 to 3.7) 0.279 –16.7 (–25.7 to –7.7)<0.001
–––––––––––– ––––––––––––
Odds ratio Odds ratio
(95% CI) (95% CI)
–––––––––––– ––––––––––––
Primary behavioural measures
Brush teeth at least twice  N = 116 N = 117 N = 201 N = 165
a day
Baseline – n (%) 83 (71.6) 92 (78.6) 158 (78.6) 129 (78.2)
N = 116 N = 117 N = 201 N = 165
Follow-up – n (%) 83 (71.6) 100 (85.5) 158 (78.6) 143 (86.7)
2.8 (1.2 to 6.9) 0.021 2.1 (1.2 to 3.6) 0.006
Brush teeth for at least  N = 116 N = 116 N = 201 N = 165
2 minutes
Baseline – n (%) 44 (37.9) 32 (27.6) 81 (40.3) 69 (41.8)
N = 116 N = 116 N = 201 N = 165
Follow-up – n (%) 51 (44.0) 68 (58.6) 91 (45.3) 117 (70.9)
3.3 (1.7 to 6.5) <0.001 3.0 (1.9 to 4.8) <0.001
Rinse but do not spit N = 111 N = 113 N = 199 N = 161
Baseline – n (%) 31 (27.9) 23 (20.4) 56 (28.1) 45 (28.0)
N = 111 N = 113 N = 199 N = 161
Follow-up – n (%) 40 (36.0) 62 (54.9) 62 (31.2) 105 (65.2)
3.5 (1.8 to 6.6) <0.001  5.3 (3.6 to 7.8) <0.001
a Analysis adjusted for baseline measures.
b Analysis adjusted for baseline measures and clustering of patients within vocational dental practitioner.and 8 provide some evidence that partial
contamination did occur, but that it was unlikely
that the magnitude of contamination differed
substantially between the patient and cluster
randomised trials. We hypothesised a priori that
the effect sizes for the patient randomised trial
would be less than those in the cluster randomised
trial because of contamination. In the clinical
outcomes, such a trend was observed, and, if taken
at face value, would indicate that contamination in
the patient randomised trial reduced the effect
size from –16.7 to –4.5%. However, the
behavioural and cognitive measures did not show
such a consistent trend. Given that we expected
changes in behaviour and cognitions to correlate
with changes in clinical outcome, it was suggestive
that contamination was not the primary factor for
the clinical outcomes to differ.
The measures of possible contamination in Table 8
indicated that the level of contamination ranged
from 6.9 to 13.5% in the patient randomised trial
and from 4.7 to 16.4% in the cluster randomised
trial. Within each measure, the difference in
contamination between the patient and cluster
randomised trials was approximately 3–4%, but
did not consistently favour either of the trial
designs.
In conclusion, this study demonstrated that some
form of contamination occurred in both the
patient and cluster randomised trials. Hence,
although the cluster randomised trial design did
not allow control patients to get the evidence-
based oral hygiene advice intervention,
nevertheless, some patients did acquire some of
the knowledge (and electric toothbrush) during
the follow-up phase. Further work is currently
being undertaken to explore further the possible
mechanisms and impact of this contamination on
the results of the trials.
Conclusion
When considering all studies targeted at health
professionals and reviewed by Grimshaw and
colleagues,14 there is no clear evidence that the
effectiveness estimate in trials that do not avoid
contamination is biased, compared with trials
where contamination is avoided. However, when
analysing more homogeneous and higher quality
trials, those in which contamination was avoided
by cluster randomisation tended to have larger
effects. Our analysis of homogeneous trials of
smoking cessation interventions targeted at
patients found some evidence that trials that
avoided contamination by cluster randomisation
tended to show greater effects. The trial that
directly compared effect estimates following
cluster randomisation with effect estimates
following individual randomisation also showed
larger effects with cluster randomisation, but this
could have been due to biased measurement
rather than contamination. Overall, the published
evidence of bias caused by contamination in trials
of educational interventions is thus suggestive but
weak. Several other possible reasons (discussed in
the section ‘All studies analysis’, p. 11) could
explain these findings.
Health Technology Assessment 2007; Vol. 11: No. 43
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TABLE 8 Patient-reported measures of possible compliance
Patient reported Patient randomised trial Cluster randomised trial
Control Intervention Control Intervention
n (%) n (%) n (%) n (%)
Changed from manual to electric toothbrush at follow-up 9 (8.2) 68 (60.2) 9 (4.7) 108 (69.2)
Changed to brushing teeth at least twice a day at follow-up 8 (6.9) 10 (8.5) 9 (4.5) 19 (11.5)
Changed to brushing teeth for at least 2 min at follow-up 15 (12.9) 37 (31.9) 33 (16.4) 59 (35.8)
Changed to rinsing but not spitting at follow-up 15 (13.5) 41 (36.3) 18 (9.0) 64 (39.8)A
lthough there is little published evidence of 
the effects of contamination, many
educational researchers and trialists have
experience in conducting and analysing trials of
educational interventions in which contamination
was a potential problem. We used a Delphi
method to summarise their expert judgements so
as to identify situations in which contamination is
most likely and how to avoid it. The Delphi
method is an exercise in group communication
among a panel of geographically dispersed
experts.232 The technique recognises human
judgement as legitimate and useful input and
allows experts to deal systematically with a
complex problem or task and to generate
forecasts. It comprises a series of questionnaires
sent, either by mail or by computerised system, to
a preselected group of experts and interspersed
with controlled feedback of opinion.232 The
questionnaires are designed to elicit and develop
individual responses to the questions posed and to
enable the experts to refine their views as the
group’s work progresses in accordance with the
assigned task. The principle of the Delphi method
is to overcome the disadvantages of conventional
committee action. According to Fowles,233
anonymity, controlled feedback and statistical
response characterise Delphi. The group
interaction in Delphi is anonymous, in the sense
that comments, forecasts and the like are not
identified as to their originator but are presented
to the group in such a way as to suppress any
identification.
Our objective for the Delphi study was to elicit
expert opinion with regard to the situations in
which contamination and contamination
avoidance were most likely.
Methods
The Delphi questionnaire was administered over
three rounds:
1. Pilot round: the pilot study was distributed to a
small group of experts. The aims were to
ensure intelligibility of the questions, clear
design of the questionnaire and adequate
freedom to express opinions.
2. First round: the questionnaire was distributed
individually to over 100 medical education
experts, including those who completed the
pilot round, and to members of the Association
for the Study of Medical Education (ASME).
This round was used to establish initial
opinions of experts to inform the second
round.
3. Second round: the questionnaire was
distributed to all respondents to the first round.
The second-round questions matched those in
the first round, but allowed each respondent to
view the popularity of each response in the
previous round. Additionally, the second-round
questionnaire incorporated a ranking exercise,
based on first-round opinions, to identify
design factors most likely to lead to
contamination. Furthermore, in response to
subjects’ comments on the first round, we
added two new sets of questions, as described
below. 
The questionnaires were disseminated via the
Internet. The online questionnaires were
constructed by Priority Research Ltd, Sheffield.
Responses to the various questions were made via
check boxes, for multiple-choice responses, and by
free text entry. Respondents were invited to
participate via email. Email reminders to potential
respondents were also used. By this method,
postal delays and data entry from paper copies
were avoided, and reminders did not require
additional paperwork or postage.
The pilot round of the Delphi was used primarily
to assess the suitability and clarity of the
questionnaire. The respondents invited to
participate in this round were restricted to
researchers involved in the project. This round led
to re-wording of questions, an extension of the
definitions and an increase in the Likert scale
from three options (‘highly likely’, ‘neither likely
nor unlikely’, ‘highly unlikely’) to include the two
intermediate points, ‘moderately likely’ and
‘moderately unlikely’. The option ‘no
comment/not sure’ was added for each item.
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Expert opinion on situations most likely to lead 
to contamination and how to avoid itThe study sample was identified as follows. We
compiled a list of experts known to be active in
educational research in health. Our personal
knowledge was supplemented by searches of
researchers active in relevant Cochrane
Collaboration and Campbell Collaboration
groups. This list consisted of over 100 people to
whom the first round of the Delphi questionnaire
was emailed. It was also emailed to all members of
the ASME. Each email contained an overview of
the study, an invitation to participate and an
attached covering letter. The letter and email
contained hypertext links both to the online
Delphi questionnaire and the research project’s
website. A total of 37 individuals completed the
first-round questionnaire and were included in the
second round and 27 completed the second
round.
Questionnaire design 
The first section of the questionnaire elicited
respondents’ views on the likelihood of
contamination in various circumstances. They were
asked to consider each factor in isolation,
assuming that other factors were the same. To
maximise the final response rate by limiting the
number of rounds required, the questionnaire was
based on our knowledge and on expert opinions
expressed in the literature, instead of starting with
elicitation of relevant factors from respondents.
Respondents were able, however, to suggest other
factors that should be considered.
The questions covered the following categories:
1. aim of interventions: transferring knowledge,
skills, altering behaviour and changing
attitudes
2. complexity of interventions
3. intervention targets: patients, professionals or
the general public
4. movement of individuals between treatment
arms
5. geographical separation of trial subjects
6. social separation of trial subjects
7. desirability of the interventions
8. transferability of the interventions
9. educating participants against contamination
10. different trial designs 
11. situations where cluster randomisation is
needed
12. the medium of the intervention, i.e. booklet,
CD, etc.
13. social, occupational and geographical
proximity of patients
14. social, occupational and geographical
proximity of professionals.
For each factor within these categories,
respondents indicated how likely they thought
contamination was in that situation. In order to
analyse these results, a scoring system was used.
The possible responses are given below with their
scores in brackets. Usage of these scores will be
explained later.
● highly likely (5)
● moderately likely (4)
● neither likely nor unlikely (3)
● moderately unlikely (2)
● highly unlikely (1)
● don’t know/not applicable (0).
Most of the questions in this first section of the
questionnaire required multiple-choice responses.
There were two opportunities to make free text
responses. One could be used to suggest
additional mediums of intervention that were
likely to lead to contamination. The other could
be used to state specific situations in which cluster
randomisation should be used to avoid
contamination. Additionally, we asked respondents
to make free text responses to the following
specific questions:
1. How do you think researchers can protect
against contamination in controlled trials of
educational interventions?
2. Under which circumstances would you employ
a particular study design specifically to avoid
contamination?
3. How would you know if contamination were
occurring in a study?
The first-round questionnaire also allowed free
text responses to be made in order to comment
generally on the questionnaire, improve the clarity
of the questionnaire, modify the definitions
provided or list any issues regarding
contamination that were not covered by the
questionnaire.
In order to compare different types of factors with
regard to their likelihood of contamination, a
scoring system was used. The number of subjects
who gave each response to each question was
multiplied by that response’s score to produce a
mean score for each question. The resulting values
were summed and the results divided by the
number of responses. For example, if two
respondents give the answer ‘highly likely’ (score
5) and one respondent gives the answer ‘neither
likely nor unlikely’ (score 3), the mean score would
be [(2 × 5) + (1 × 3)]/3 = 4.33. Using this method,
a high score indicates a high likelihood of
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either a low likelihood of contamination or a high
level of uncertainty [i.e. ‘don’t know’ responses
(score 0)].
The aim of the second round was to elicit a
consensus of the first-round responses in terms of
their likelihood to lead to contamination. The
second-round questionnaire was largely identical
to the first-round questionnaire, but provided
additional information about first-round
responses. Each respondent was provided with the
same questions (minus the free text questions),
and was asked to consider their response in the
light of the other experts’ opinions. For each
question they were presented with a percentage
breakdown of the response by all experts and
reminded of their previous response.
The second-round questionnaire included a new
section. Respondents were presented with two
examples of an intervention which, in accordance
with first-round responses, was highly likely to lead
to contamination. Each intervention was assumed
to be:
● highly desirable
● made up from simple elements that stand alone 
● aimed at transferring new knowledge and
● easy to transfer.
One example, of an intervention aimed at
patients, was a workout video to aid weight loss.
The other example, of an intervention aimed at
patients, was a CD-based computer program for
managing diabetes in primary care using National
Institute for Health and Clinical Excellence
guidelines. For each example, respondents were
presented with a ranking of the eight factors
deemed generally most likely to lead to
contamination, according to first-round responses.
Respondents were asked either to agree with this
ranking or to specify a new ranking.
Examples of the first- and second-round
questionnaires are provided in Appendices 1 and
2, respectively. The definitions provided to
respondents are given in Appendix 3.
Results
Scores for the second round were very similar to
those for the first round (R2 = 0.98). Table 9 shows
the ranking within each question, in the order in
which it was asked. Table 10 re-ranks the items
under three general headings so as to facilitate
comparisons. Our scoring method entails that
items in the top 27 ranks were, on average,
considered more likely than unlikely to lead to
contamination. A detailed breakdown of responses
to the first and second rounds is available from the
first author.
The results show that, in the opinion of
respondents, contamination was most likely to
occur in trials conducted in settings where subjects
worked, lived or interacted closely together and
where interventions were desirable, simple or
easily transferable or were aimed at increasing
knowledge. Contamination was least likely where
subjects were socially or physically separate, 
where interventions were complex or aimed at
changing behaviours and when cluster
randomisation was used. Contamination was more
likely with interventions aimed at health
professionals than with interventions aimed at
patients. It was more likely with interventions
based on broadcast media, audiovisuals or written
information, was least likely with computer-based
reminders, and was intermediate with training
interventions. 
For each of the two scenarios in which
contamination was stated in advance to be likely,
additional factors more or less likely to cause
contamination were ranked as follows. For the
patient education scenario – comprising an
exercise workout video – the location and
movement of patients were ranked as more likely
to cause contamination than professional-related
factors (Table 11). Contamination was more likely if
intervention and control patients lived in the same
residence than if they shared social networks or
geographical location.
For the professional education scenario – 
CD-based diabetes guidelines – the location and
movement of health professionals were ranked as
more likely to cause contamination than patient-
related factors (Table 12). Working in the same
workplace was more likely to cause contamination
than moving between intervention and control
arms or sharing a place of employment. 
Free text responses
When asked, ‘Are there any situations which
usually require cluster randomisation to avoid
contamination?’, their responses were as follows:
● When the intervention is delivered by a health
professional (nine responses).
● Individually randomised trial where the
participants are likely to meet (four responses).
● General public or mass media interventions
(four responses).
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desirable, and the physical/social/trial design
conditions make that possible/likely’ (one
response).
● ‘Cluster randomisation is usually required for
logistical reasons not because of fears of
contamination’ (one response).
When asked how respondents thought researchers
can protect against contamination in controlled
educational intervention studies, their responses
included the following:
● Cluster randomisation (or equivalent, i.e.
geographical/social separation) (18 responses).
● Educate against contamination (six responses).
● Don’t educate against contamination (two
responses).
● Provide clear information on nature and
purpose of study and on the intervention and
controls (four responses).
● Attempt to measure contamination (three
responses).
● You cannot protect against contamination/can’t
do much (three responses).
● Increase sample size to compensate (two
responses).
● Use less transferable interventions (two
responses). 
● ‘(a) Expect it, (b) design it out as far as possible
– using the usual methods – as much blindness
as possible’ (one response).
Asked under which circumstances they would
employ a particular study design specifically to
avoid contamination, several suggested a cluster
randomised design for the following situations:
● When educating health professionals (five
responses).
● When the intervention cannot be delivered at
individual level (two responses).
● When the intervention occurs at population
levels (two responses).
● When individuals are likely to discuss
intervention (two responses).
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TABLE 9 Likelihooda of contamination for different intervention characteristics, contexts or trial designs, ranked within each question
Intervention characteristic, context or  Score Intervention characteristic, context or  Score
trial design trial design
Transfer of new knowledge 3.89
Changing attitudes 2.63
Transfer of new skills 2.59
Altering behaviours 2.52
Simple – elements stand alone 3.78
Modest complexity – some elements stand alone 3.33
Complex – multiple interdependent parts 2.44
Targeted at health professionals 4.07
Targeted at patients 3.26
Targeted at the general population 2.89
Staff move from intervention arm to control arm 4.59
Patients move intervention arm to control arm 3.96
Subjects from the same geographical site 4.22
Subjects from nearby sites in same community 3.52
Subjects geographically separated 1.74
Subjects from same social networks 4.78
Subjects from overlapping social networks 3.96
Subjects unlikely to have social networks in common 1.52
High desirability 4.07
Medium desirability 3.04
Little desirability 1.85
Easy to transfer 3.78
Difficult to transfer 1.56
No efforts to educate participants against  3.67
contamination
Participants educated to avoid contamination 2.26
a Higher score indicates greater likelihood. Scores from Delphi second round.
Individually randomised parallel group trial 3.59
Before/after comparisons 2.37
Repeated time series 2.37
Cluster randomised trial 2.08
Broadcast media (TV, radio) 4.44
Audiovisual, e.g. video, CD-ROM 3.93
Written information, e.g. booklet 3.89
Training programme (multiple attendances) 2.41
Training event (single attendance) 2.38
Use of specialist resources (models, simulations) 2.04
Computer reminders (popups on computer) 1.93
Patients living in the same residence 4.93
Patients with shared social networks 4.19
Patients’ healthcare comes from same practice 3.89
Patients living in same geographical locality 3.74
Health professionals in the same workplace team 4.78
Health professionals sharing a place of employment 4.37
Health professionals in the same clinical 
directorate or equivalent 3.85
Health professionals sharing an employer 3.33
Geographical/social separation of subjects 4.00
Education of subjects to avoid transfer of  3.37
intervention
Restriction on medium of intervention 3.19
Avoid allocation of subjects to less desirable arm 2.48● When there is a strong likelihood of
contamination (two responses).
Several wrote that the main reason for doing
cluster randomised trials was that the unit of
inference was a professional or workplace and so it
was logical to randomise at this level. Other
designs suggested included the following:
● Use an interrupted time series design to collect
control data before the intervention (two
responses).
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TABLE 10 Likelihooda of contamination ranked within intervention characteristics, contexts or trial designs, and each question
Characteristic Score Characteristic Score
Content, medium or aim of intervention
Media output (TV, radio) 4.44
High desirability 4.07
Audiovisual, e.g. video, CD-ROM 3.93
Transfer of new knowledge 3.89
Written information, e.g. booklet 3.89
Simple elements stand alone 3.78
Elements easy to transfer 3.78
Modest complexity – some elements stand alone 3.33
Medium desirability 3.04
Aimed at changing attitudes 2.63
Aimed at transfer of skills 2.59
Aimed at altering behaviours 2.52
Complex – multiple interdependent parts 2.44
Training programme (multiple attendances) 2.41
Training event (single attendance) 2.38
Use of specialist resources (models, simulations) 2.04
Computer reminders (popups on computer) 1.93
Little desirability 1.85
Elements difficult to transfer 1.56
Context or setting of intervention
Patients living in the same residence 4.93
Subjects from same social networks 4.78
Health professionals in the same workplace team 4.78
Staff move from intervention arm to control arm 4.59
Health professionals sharing a place of employment 4.37
Subjects from the same geographical site 4.22
Patients with shared social networks 4.19
Targeted at health professionals 4.07
Patients move from intervention arm to control arm 3.96
Subjects from overlapping social networks 3.96
Patients’ healthcare comes from same practice 3.89
Health professionals in same clinical directorate  3.85
or equivalent
Patients living in same geographical locality 3.74
Subjects from nearby sites in the same community 3.52
Health professionals sharing an employer 3.33
Targeted at patients 3.26
Targeted at the general population 2.89
Geographically separated 1.74
Subjects unlikely to have social networks in common 1.52
Design or conduct of trial
Geographical/social separation of subjects 4.00
No efforts to educate participants against  3.67
contamination
Individually randomised parallel group trial 3.59
Restriction on medium of intervention 3.19
Avoid allocation of subjects to less desirable arm 2.48
Before/after comparisons 2.37
Repeated time series 2.37
Education of participants to avoid transfer of  3.37
intervention
Participants educated to avoid contamination 2.26
Cluster randomised trial 2.08
a Higher score indicates greater likelihood. Scores from Delphi second round.
TABLE 11 Likelihood of contamination with a patient-targeted intervention
Patient target  Revised SD Original  Change
rank rank
Patients receiving the intervention live in the same residence as patients receiving  1.6 0.69 2 0.4
the control
Patients receiving the intervention are from the same social network as patients  3.1 1.15 3 –0.1
receiving the control
Patients move from intervention arm to control arm 3.9 2.57 7 3.1
Health professionals administering the intervention are in the same workplace  4.3 2.16 1 –3.3
team as health professionals administering the control
Staff move from intervention arm to control arm 5.5 1.68 4 –1.5
Patients receiving the intervention are from the same geographical site as patients  5.5 1.76 6 0.5
receiving the control
No effort is made to educate participants against contamination 6.1 2.21 8 1.9
Health professionals in the intervention arm share a place of employment  6.2 1.19 5 –1.2
with health professionals in the control arm● Find a balance between contamination sample
size and cost (two responses).
Asked how they would know if contamination were
occurring in a study, their responses included the
following:
● Measure it by questioning control group (13
responses).
● Look for delayed parallel improvement in
control arm (two responses).
● ‘Comparison with non-study samples’ (one
response) 
● ‘Very difficult without totally independent
control groups’ (one response).
Asked how to improve the questionnaire, several
respondents wrote that they would have preferred
more specific examples to have been provided or
would have preferred a more specific context to be
given for some of the questions. Several
commented that holding the assumption of ‘other
things being equal’ while considering each factor
in isolation did not make sense because the risk of
contamination depended on combinations of
factors.
Discussion
These results reflect the opinions of experts in
educational research on study designs to avoid
contamination, and give some guidance to those
designing trials of educational studies. There was
a high degree of consensus among these experts.
Many of the findings have face validity and may
even seem obvious. However, they are worth
considering when contamination is possible. They
suggest that researchers should consider using a
cluster randomised design, or take stringent
efforts to avoid and measure contamination, in the
following settings where contamination is most
likely:
● any groups working in the same healthcare
setting, or living in the same household
● any group with significant social network
linkage (e.g. GPs in the same community)
● media-based interventions. 
Interventions with less risk of contamination
include multifaceted interventions and those with a
significant behavioural component that cannot
easily be transferred from one participant to
another. Experts were sceptical about the value of
specific preventive instruction in reducing
contamination, particularly in patient-based
interventions. The consensus was that, for cluster
randomised designs, contamination was more likely
where both the intervention and control health
professionals were part of the same workplace
team. In these situations, early contamination of
all, or a large proportion of, the cluster may occur.
Rapid contamination of a large proportion of a
cluster might also occur when a health professional
moves from the intervention to the control group. 
In conclusion, there may be practical or logical
reasons, unrelated to contamination, to use cluster
or individually randomised trials designs to
evaluate educational interventions. However, the
findings of this study give some guidance on the
types of studies for which cluster randomised
designs may be best. As this study shows, there are
many other ways to avoid contamination if it is a
risk.
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TABLE 12 Likelihood of contamination with a professional-targeted intervention
Patient target  Revised SD Original  Change
rank rank
Health professionals receiving the intervention are in the same workplace team  1.8 1.57 1 –0.8
as health professionals receiving the control
Staff move from intervention arm to control arm 3.2 1.70 4 0.8
Patients in the intervention group live in the same residence as patients in the  3.6 1.80 2 –1.6
control group
Health professionals receiving the intervention share a place of employment  4.4 1.41 5 0.6
with health professionals receiving the control
Patients in the intervention group are from the same social network as patients  4.8 1.78 3 –1.8
in the control group
Patients move from intervention arm to control arm 5.4 1.93 7 1.6
No effort is made to educate participants against contamination 6.2 2.40 8 1.8
Patients in the intervention group are from the same geographical site as patients  6.6 1.08 6 –0.6
in the control groupI
n order to examine the influence of
contamination upon a trial, simulation
programs were produced to reflect the effect of
the intervention and contamination upon the
experimental and control groups. 
Aim
The aim of our simulation program was to
compare the bias of cluster randomised trials
relative to the bias of individually randomised
trials. Contamination was modelled in both
individual and cluster randomised trials under
different scenarios. 
Methods
Bias of the effectiveness estimate is a function 
of three components of the contamination 
process:
1. The proportion of the control group exposed
to the intervention. 
(a) The proportion exposed may or may not
be a function of subjects’ baseline ‘need’
for the intervention, that is, according to
the baseline value of the outcome measure.
2. The timing of the exposure.
(a) In cluster randomised trials, individual
control subjects may be exposed either at 
the time of the cluster’s first exposure, 
or later.
3. The intensity of exposure.
These variables all vary randomly between control
subjects. Any of these components could also be a
function of the desirability or transportability of
the intervention, which do not need to be
modelled separately.
For example, consider a trial of training GPs to
use a clinical practice guideline. All or some of the
control group GPs could inadvertently receive the
guideline. Those who do could be those who are
less or more informed. They could receive the
guideline but not the training. In a cluster
randomised trial, control practices could start
receiving the guideline after intervention
practices, and individual GPs in these practices
could receive the guideline together then, or later. 
The contamination simulation was written in SAS
version 8. Whereas the basis of the contamination
model remained consistent, two main versions of
the simulation were produced: one to implement
an individually randomised design and the other
to implement a cluster randomised design. Both
designs of simulation were based on a two-armed
trial consisting of an intervention which is
assumed to be effective and a no-intervention
control. The outcomes in the arms of the trial are
modelled as the ‘education’ level of trial subjects
so that intervention leads to increased levels of
education.
Model for simulation
The individually randomised trial simulation
implemented the following mathematical models
for control and intervention:
yi0 = x + i0
yiT = x + i0+ it
where x ~ N(40,500), yiT is the education level for
participant i at time T, the end of the trial, yi0 is
the baseline education level of participant i,  is
the intervention effect and  is a proportion
between 0 and 1 and it ~ N (0,125) are random
errors.
This model induces a positive correlation between
the baseline and follow-up education levels.
For those individuals in the intervention group 
is fixed at one, for those in the control, with no
contamination,  is fixed at zero, and for those
contaminated,  takes on a value above zero,
possibly equal to one.
Cluster randomised trials
The cluster randomised model implemented a
similar mathematical model to that of the
individual model, but includes some additional
terms. The control and intervention models are of
the following form:
yi0 = x + i
ij0 + 
j
ij0
yiT = x =  + c + i
ijT + 
j
ijT
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Contamination simulationwhere x~N(40,500), yiT is the education level for
participant i at time T, the end of the trial, yi0 is
the baseline education level of participant i,  is
the intervention effect,  is a proportion between
0 and 1, i
ij ~ N(0, W
2) are individual random
errors, 
j
ij ~ N(0, B
2) are cluster random 
errors, B
2 and W
2 are the between-group 
and within-group variances respectively, 
B
2 + W
2 = 125 and C ~ N(0, 0.1) is the 
cluster effect variation.
For those individuals in the intervention group 
is fixed at one, for those in the control, with no
contamination,  is fixed at zero and for those
contaminated,  takes on a value above zero,
possibly equal to one; C is zero in the control
model. 
The intervention effect, , was arbitrarily set at
100. For those individuals in the intervention
group  is fixed at one, for those in the control,
with no contamination,  is fixed at zero and for
those contaminated,  takes on a value above zero,
possibly equal to one.
The above model is used for all of our simulations.
However, by varying the contamination parameter
 and its dependence on other parameters, 
it is possible to model contamination in 
different ways.
Modelling time to contamination
Time to contamination in individually randomised
trials
The time of contamination was modelled using a
Weibull distribution. It is widely used for
modelling time to event data and is an obvious
choice of model for time to contamination. 
The random variable Y follows a Weibull
probability model with parameters  > 0 and
 > 0 denoted Y ~ Weibull(, ), when Y has a
power hazard of the form h(y) = (/)y–1.
By modelling time to contamination in this way,
individuals can be labelled as contaminated or
not. For a trial of length time T, an individual i is
only contaminated if ti < T.
Since generating random variates from a Weibull
distribution is not a standard function in SAS,
variates from an exponential distribution were
generated and then transformed into Weibull
variates.
The transformation of a standard exponential
random variate x into a Weibull random variate y
with shape parameter  and scale parameter  can
be accomplished via the expression
y = x1/
where  and  are as defined above.
The hazard function, h(t), of the Weibull
distribution provides the instantaneous risk of
contamination occurring at time point t given that
contamination has not occurred by that stage.
Mathematically it is defined by
h(t) = t–1/, where  is the shape parameter
and  the scale parameter of the Weibull
distribution, given above. By altering , the nature
of the risk of contamination with time can be
varied. The parameter  controls the overall, or
average, level of risk.
For  = 1,  = h(t) = 1/; this provides a constant
hazard, that is, a constant risk of contamination
over time. To ensure a hazard function between
zero and one,  needs to be >1.
For  = 2,  = h(t) = 2t/2; this provides a hazard
which increases linearly over time. To ensure a
hazard function between zero and one,  needs to
be >√
–
2.
For  = 3,  = h(t) = 3t2/3; this provides a hazard
which increases quadratically over time. To ensure
a hazard function between zero and one,  needs
to be >3√
–
3.
In order to relate the risk of contamination to an
individual’s baseline education level yi0, the
parameter , and hence the hazard function,
varied across individuals according to yi0 via the
function
i = f(yi0) = √
–
exp[k – b(yi0 – µ)]
where √
–
 is the lower limit for , 	 is the mean
education level at baseline, b determines the
variation in  and the influence of the baseline
education level yi0, k determines the average level of
 and the exponent prevents negative values of . 
Therefore, the risk of contamination will depend
on the value of kj (a lower value of producing
higher levels of risk) and the dependence of
contamination on ignorance will be determined by
b (a higher value providing a greater dependence
and a value of zero producing no relationship
between the risk of contamination and baseline
education level).
Contamination simulation
34Time to contamination in cluster
randomised trials
Contamination of clusters uses the same model to
simulate contamination time; the Weibull random
variates are used to provide times to contamination
within the trial period. A Weibull variate is
generated for each cluster but, in addition, a
Weibull variate is generated for each subject within
clusters. 
In this way, two independent contamination time
values, tc and ti, for the cluster c and individual i
are generated according to the Weibull
distributions detailed earlier. The cluster
contamination time depends only on the
parameter kc (since no baseline education value is
generated for a cluster), via the parameter , that
is,  = √
–
exp(kc).
Two versions of cluster contamination were
considered. First, individuals were considered
independently once the cluster of which they were
members was contaminated. In this case, an
individual i within cluster c is contaminated if
tc + ti < T. 
In the second version of cluster contamination, all
individuals within the contaminated cluster were
considered to be contaminated at the time when
contamination first enters the cluster. The time at
which cluster contamination occurs is generated in
the same way as for other cluster models.
However, no use is made of the individual
contamination times within the cluster. Therefore,
for a trial of length T, all individuals within cluster
c are contaminated if tc < T, otherwise no
individuals in cluster c are contaminated. 
Contamination levels
Two options for the amount of contamination to
occur were considered. One option was to fix  to
a constant proportion for all individuals
contaminated. The second option was to make 
dependent on the time at which contamination
occurred. 
Using the same Weibull contamination times as in
the above description, the contamination time can
be converted to a simple indicator without directly
influencing the extent to which contamination
takes place.
Under the option of a constant contamination
effect, those patients who were contaminated
during the period received a constant intervention
effect, for example,  = 0.5,  = 1, that is, 50 or
100% of the intervention’s true effect, respectively. 
This constant effect simulation reflects the situation
where contamination has an instantaneous effect,
but the strength of that effect may be limited. For
example, a constant contamination effect of 100%
would be experienced by a control group patient
who received and acted upon a reminder
intervention for immunisation. Alternatively, 
a 50% effect might be achieved by a control 
group professional receiving instruction on a
particular procedure from an intervention
colleague. Awareness of the technique would
produce an immediate effect but, since training 
in the procedure was informal and secondhand, 
an imperfect technique results, reducing the 
effect.
In the second option, the proportion of
contamination was made dependent on the time
at which contamination occurs. Given a trial
duration of T and contamination occurring at
time t,  = (T – t)/T, that is, the proportion of
contamination is equal to the proportion of time
remaining in the study. 
This time-dependent contamination illustrates a
situation where the intervention has a gradual
effect on the respondent, where the full effect
requires exposure for the entire trial duration. 
For example, dietary advice for weight loss 
will only have an effect where the subject has 
time to implement the advice and change 
their eating habits: contamination at the
beginning of the trial might enable the full effect
to be received by members of the control group,
but late contamination would have little or no
effect.
Where the effect of the cluster contamination is
dependent on time, the proportion  of the
intervention effect used to contaminate individual
i within cluster c will be [T – (tc + ti)]/T, 
where tc and ti are the cluster and individual
contamination times, respectively. This 
model mimics an intervention similar to the
weight loss example given for individual 
time-dependent simulations; however, in 
order for an individual to be contaminated, 
their cluster must first be contaminated, which
takes time tc before the individual can be 
contaminated. 
Implementation
The input parameters for the SAS simulation were
as follows:
● Cycles: the number of trial simulations to
perform
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simulation program only)
● b: the parameter detailed above for the
individuals
● ICC: the intracluster correlation coefficient
(cluster simulation program only) 
● NumClusts: number of clusters in the trial
(cluster simulation program only)
● NumperClust: number of individuals per cluster
(cluster simulation program only)
● Trialsize: total number of subjects in the trial
(individual randomisation simulation program
only)
● : true intervention effect
● k: the parameter k detailed above
● PropEff: proportion of the effect to be used for
contamination (fixed effect/all or nothing
simulation programs only).
Other parameters used in the model were either
fixed or calculated from other parameters. 
For example, the total variance was set to 
125, and the variance within and between 
groups was calculated from this value using 
the ICC.
The input parameters b, kc and k were selected in
order to provide a variety of contamination 
effects whilst minimising the number of simulation
runs required. Three values of kc were used, 
0.01, 0.05 and 0.1, four values of b were used, 
0 (representing contamination independent of
individual’s need), 0.01, 0.3 and 2, and three
values of k were also used, 1, 5 and 20. Therefore,
leaving all other inputs fixed, 36 simulations were
produced.
Since 36 sets of simulations were produced for
each size, ICC, proportion of effect and type of
contamination dependence trial, the number 
of cycles chosen for initial analysis was chosen to
be 100. This number was sufficiently large to
enable results to be reliable, but necessarily 
small enough to obtain results within a reasonable
timescale. A single set of 36 simulations 
for time-dependent, fixed and all or nothing
contamination took approximately 2–3 hours for
100 cycles, whereas 1000 cycles took between 16
and 24 hours to run.
For each type of contamination dependence, a set
of 36 cluster simulations with 100 cycles was
performed for ICC = 0.2 and 0.01. For both of
these ICC values, sets of simulations were
performed for trials of the following 
dimensions:
● 20 clusters of five subjects
● five clusters of 20 subjects
● 10 clusters of 10 subjects.
Corresponding individual simulations with trial
size 100, using the same values of k and b, were
produced.
Larger scale simulations were also produced with
the same ICCs. These simulations consisted of 10
clusters of 100 individuals and were compared
with the results from an individually randomised
simulation with trial size 1000. 
The outcome of interest for each simulation was
the bias through contamination and a comparison
between the individual randomised design and the
cluster randomised design. The bias was defined
as the difference between the true intervention
effect and the apparent intervention effect, that is,
the mean difference between intervention and
control at follow-up.
Parameters
For each of the three types of hazard functions
( = 1, 2, 3), the values of output by the
simulation are the following:
● proportion contaminated (%)
● bias due to contamination (mean, SD, upper
and lower 95% CI)
● follow-up education level (overall, contaminated
subjects only and not contaminated 
subjects only, each of these at baseline and
follow-up)
● contamination time (individual, cluster and
overall, overall for those contaminated, overall
for those not contaminated).
The parameter b controls the variance of the
contamination times for individuals once
awareness of the intervention is possible. As b
increases, the contamination times of individuals
with greatest need decrease, and the
contamination times of individuals with least need
increase. An illustration of the effect of k and b is
given in Figure 29.
The parameter kc causes a positive shift in the
overall contamination times. Therefore, as kc
increases, there is no change to the spread of
contamination times, but all contamination times
are increased by a fixed constant (
0). Conversion
of the parameter kc into a more meaningful time
elapsed and percentage of trial elapsed value is
shown in Table 13.
Contamination simulation
36Results
The results from all simulations for all outputs are
available from the first author. The figures
provided are the bias through contamination for
the individually randomised trial and the
difference in bias through a cluster randomised
trial in the same situation. A negative difference
implies greater bias for the cluster randomised
trial. This difference is also expressed as a
percentage of the individually randomised
simulation’s effect. The percentage decrease in
contamination time of the individual simulation
compared with the cluster is also included,
together with the baseline education level for both
contaminated and not contaminated subjects.
b = 0 (no influence of baseline
education on risk of contamination) all
cluster members contaminated
When contamination of a cluster affected all
cluster members there was a greater bias for
cluster randomised trials compared to individually
randomised in almost all scenarios. For a constant
contamination level (i.e.  = 1), as given in
Table 14, the bias in both forms of trials was
around 100 in many instances. For a high level of
k (i.e. a long average individual contamination
time) bias dropped off to zero for the individually
randomised trial, but was frequently very high in
the cluster randomised trial.
For time-dependent contamination level (i.e. 
depending on time), as given in Table 15, the
results were not clear cut. There appeared to be an
advantage in cluster randomisation only when
k = 1 (i.e. a short average individual
contamination time). This seemed particularly to
be the case with a non-constant hazard of
contamination, that is, risk of contamination
increasing with time.
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For small b
Trial time
Most need Least need
k
For large b
Trial time
Most need Least need
k
= Contamination times
FIGURE 29 Effect on time of contamination of altering b (education dependence of time of contamination) while holding k (mean
time of contamination) constant
TABLE 13 Conversion of parameter kc into expected time and percentage of trial elapsed
Exponential  = 1 Linear Weibull  = 2 Linear Weibull  = 3
kc Time (approx.) % of trial  Time (approx.) % of trial  Time (approx.) % of trial 
0.01 1.49 12 1.86 16 1.92 16
0.05 4.45 37 6.95 58 8.1 68
0.1 6.65 55 11.95 99 12.84 100T
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education on risk of contamination)
individual contamination post cluster
contamination
For a fixed contamination effect, as given in
Table 16, there appeared to be a small, moderate or
potentially large advantage to cluster
randomisation. For constant contamination
( = 0.5), the reduction in bias from cluster
randomisation was most apparent when k = 1 (i.e. a
short average time to individual contamination),
and kc was relatively large (i.e. a long average time
to cluster contamination), as one might expect. For
time-dependent contamination, as given in Table 17,
the pattern was the same but a greater advantage
from cluster randomisation was apparent.
b = 0.3 (moderate influence of baseline
education on risk of contamination) all
cluster members contaminated
For a fixed contamination effect, as given in
Table 18, there was a substantial increase in bias for
the cluster randomised design in many situations.
There was a modest advantage in the cluster
randomised design only when time to cluster
contamination was late, that is, kc = 0.1. For time-
dependent effect of contamination level, as given
in Table 19, there was an advantage to cluster
randomisation for shorter cluster contamination
times and also when the hazard increased with
time.
b = 0.3 (moderate influence of baseline
education on risk of contamination)
individual contamination post cluster
contamination
For both constant contamination effect and time-
dependent contamination effect, as given in
Tables 20 and 21, respectively, there was a general
advantage in the cluster randomised design, with
some exceptions. The reduction in bias appeared
greater for longer time to cluster contamination,
for increasing hazard with time and contamination
level dependent on time.
b = 2 (strong influence of baseline
education on risk of contamination) all
cluster members contaminated
For the constant-effect contamination model as
given in Table 22, the cluster randomised design
was only preferable for the latest cluster
contamination (kc = 0.1). The difference in bias
appeared uniform across different hazard types.
For time-dependent level of contamination, as
given in Table 23, there was again a disadvantage
for the cluster randomised design when the time
to cluster contamination was short (i.e. for
kc = 0.01). Otherwise, the bias appeared to be less
and this was more pronounced when the hazard
function increased with time. 
b = 2 (strong influence of baseline
education on risk of contamination)
individual contamination post cluster
contamination
For constant contamination effect, as given in
Table 24, there was a small to moderate advantage
for cluster randomised design. This appeared to
be independent of hazard function type. A similar
pattern was seen for time-dependent
contamination, as given in Table 25, but with a
greater difference in bias in all situations. 
Discussion
In general, the simulations showed that there are
situations where cluster randomisation is clearly an
unwise choice of design. The most noticeable of
these was the situation where contamination of a
cluster results in the contamination of all
individuals in that cluster. Simulations suggest that
individual randomisation should be used in this
situation except in cases where the risk of cluster
contamination is likely to be very small and that
for individual contamination comparatively high.
This benefit of individual randomisation is most
pronounced for contamination effects that are
constant over time. 
The simulations suggested that, when
contamination is not cluster-wide but filters
through more slowly amongst individuals, a cluster
randomised design can produce less biased results
than individually randomised designs. This
preference was most evident in situations where
contamination of clusters was delayed until late in
the trial, and in situations where a subject’s
baseline education is strongly related to their
likelihood of being contaminated. The benefits of
cluster randomisation are also more apparent
when the intensity of contamination effect is time
dependent, that is, when earlier contamination
leads to a greater effect on an individual. Further,
when the risk of contamination is not constant
with time but increases with time (e.g. when
contamination is communicated between
individuals), the benefits of cluster randomisation
are more apparent.
There appeared to be little variability in the
difference in bias with respect to cluster study
design, that is, with respect to varying cluster size
or ICC.
Contamination simulation
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LOW MED
How likely is contamination either to occur
rapidly, or to affect all members of control
clusters?
How strongly associated are subjects’ baseline need for
the intervention and their likelihood of obtaining it?
What is the likely
transferability or awareness
of the intervention among
the control group?
E.g. intervention is easy to
transfer and adopt and of
which all are aware
HIGH
LOW
LOW MEDIUM HIGH LOW MEDIUM HIGH LOW MEDIUM HIGH
What is the likely
transferability or awareness
of the intervention among
the control group?
What is the likely
transferability or awareness
of the intervention among
the control group?
MED HIGH
E.g. are all control subjects equally likely to accept what
they are allocated, or will those with least knowledge be
more likely to get the intervention?
E.g. mass media campaign
How much will the expected delay before the intervention reaches control
clusters prevent contamination?
E.g. are clusters clearly separated geographically or socially so that
contamination can only occur after some delay or is contamination likely
from the commencement of the trial?
CRCT
CRCT RCT RCT CRCT
RCT
RCT
Key
Constant
contamination
Time-dependent
contamination
CRCT Cluster randomised
controlled trial
RCT Individually randomised
controlled trial
SHORT DELAY MEDIUM DELAY LONG DELAY
FIGURE 30 Flowchart guide to cluster or individually randomised designThe results of these simulations agree broadly with
the results of our Delphi questionnaire. The
Delphi responses concluded that, for cluster
randomised designs, contamination was highly
likely where both the intervention and control
health professionals were part of the same
workplace team (rank 2): a situation that may lead
to early contamination of all or a large proportion
of the cluster. A similar rapid contamination of a
large proportion of a cluster might occur when a
health professional moves from the intervention to
the control group (rank 4).
The simulation parameters do not translate
exactly to physical aspects of trial design. However,
the results can be used as an approximate guide
with regard to situations in which cluster
randomisation is favourable and situations where
it is not. The flowchart in Figure 30 can be used as
an approximate guide in making such a decision.
The first stage of the flow chart determines
whether the proposed trial is similar to the ‘all
cluster members contaminated’ simulation or
whether individual contamination occurs after
cluster contamination. The second stage is
analogous to the parameter b and assesses the
influence of baseline education on the likely
response of subjects. The third stage relates to the
parameter k determining the speed or ease with
which contamination can occur in individuals. 
The final stage determines the delay in cluster
contamination that the proposed design will incur. 
These results are based on simulated data that
may not accurately reflect what happens during
real-world trials. It would therefore be valuable if
future individual and cluster randomised trials of
educational interventions could measure and
analyse the process of contamination and its
effects over time. 
Contamination simulation
64Background
Randomisation ensures baseline equivalence
between two or more groups that are formed,
apart from chance differences. It therefore
controls for both observed and unobserved
confounders and provides a basis for statistical
inference. It does not address other biases that
may occur after random allocation. In this report
we consider the effects of one of these biases,
namely contamination of one of the treatment
groups. 
Origins of randomised trial analysis
Modern randomised trials had their origins in
work in the 1920s in the area of experimental
agriculture by Fisher.234 It was not until the late
1940s that randomisation was adapted, by
Bradford Hill, for use in experimental
medicine.235 Although participants in medical
trials are clearly equivalent to the agricultural
plots studied in Fisher’s work, the order of the
randomisation procedures is slightly different. In
agricultural research, experimental units are
identified in advance of the trial being designed,
the allocation structure is then developed and
finally the pattern of treatment is imposed. The
situation is usually reversed in medical research,
with the randomisation sequence generated first
and then the patients recruited.236 Furthermore,
the participants in the trial (i.e. plots of land or
plants) cannot refuse the allocated therapy. Finally,
in the context of this review, contamination
between crops is less of a problem as application
of fertiliser can be applied carefully so as to avoid
contaminating control plots. 
The analysis of agricultural trials is relatively
straightforward with all allocated plots receiving
the treatment they were allocated to and then
being included in an ITT analysis.
An additional difference between agricultural and
medical research is that medical researchers are
interested in effects on individuals, whereas
agricultural researchers are not. Twice as much
grain can come from twice as many plants
surviving, or from each plant doubling its output.
The difference is irrelevant in agricultural
research, but important in medical research. In
contrast, although it is important to policy makers
and public health evaluations to be interested in
the group mean or group totals, the effects of
treatment at an individual level are also of interest
to the clinician and the patient. For example, if
this patient takes a given treatment, as prescribed,
what is the likely impact on their condition? Trials
with contamination and that use ITT analysis do
not answer this question. Rather, human trials
answer the question as whether the offer of
treatment to the intervention population is
effective, which is rather different. 
One approach that is widely used to deal with the
problem of contamination is to use ‘per protocol’
or ‘on-treatment’ analysis. Per protocol analysis is
where patients, who either do not adhere to their
treatment or who access the experimental
intervention, are discarded from the analysis.
Because this approach results in a loss of statistical
power due to a sample size reduction, some prefer
to use an on-treatment approach. This is where
contaminated participants are retained in the
analysis but are assigned to a treatment-received
group. However, for both of these analyses to be
valid the participants who do not adhere have to
be a random sample of all those participants who
were offered treatment. This is rarely true.237
Consequently, it is possible, indeed likely, that they
differ in ways that could be associated with
outcomes. If so, this will lead to bias. There are
now classic examples which emphasise the pitfalls
of these types of analyses.238–240
This drawback of per protocol or on-treatment
analysis has long been recognised. Therefore, the
use of ITT analysis was recommended as being the
principal analytical approach by Bradford Hill in
the seventh edition of his textbook Principles of
Medical Statistics.241 However, the concept of
analysing participants as randomised was reported
earlier.242 The main reason for advocating ITT is
that it maintains the baseline comparability
achieved by randomisation, unlike per protocol
and on-treatment analyses.237 If the initial
randomisation process is undermined, then
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Chapter 5
Dealing with contamination in randomised 
controlled trials using Causal Average Effect Analysisconfounding can be introduced and consequently
the internal validity of the results is questionable.
In addition, an ITT analysis is completely
objective because it guards against any conscious
or unconscious decisions that have to be made if
unexpected outcomes are observed. Many authors
also note that as an ITT analysis essentially
focuses on the effect of a change in treatment
policy, it mirrors what would happen in actual
clinical practice.243 Consequently, comparing the
outcomes of all those randomly allocated to
treatment A with all patients allocated to
treatment B allows policy decisions to be made on
whether drug A could actually replace drug B in
clinical practice.
Although an ITT analysis does, in principle,
provide an unbiased estimate of offering
treatment to all trial participants, it will, in the
presence of non-adherence or contamination,
result in a conservative or diluted estimate of the
treatment effect for patients who adhered to
treatment recommendations. ITT is a conservative
approach because ITT sacrifices the Type II error
(false negative, that is, power is reduced) rate
while controlling for Type I error (false positive)
rate. So, although ITT guards against selection
bias, it does so at the cost of introducing ‘dilution’
bias and thus reduces the power of the study.
Nevertheless, ITT will not be biased in the
direction of showing an effect when there is no
effect, apart from unusual circumstances such as
dispensing errors leading to treatments
accidentally being swapped.244 However, the
possibility of showing an effect when there is no
effect (Type I error) cannot be excluded with per
protocol or on-treatment analysis.
There are several approaches that could be
undertaken to reduce the problem of
contamination between treatment groups. Where
contamination occurs because a treatment is easily
passed on to the control group, such as a health
education intervention, cluster randomisation can
be undertaken. Physically separating groups of
participants will reduce and sometimes abolish the
threat of contamination, although this will not
deal with the issue of non-adherence, which is a
second form of contamination. There are a
number of drawbacks to cluster randomisation.
First, the sample size of the trial has to be
increased to take into account the clustered nature
of the data.245 Second, cluster trials can be difficult
to undertake properly and many suffer from
methodological errors, such as recruitment bias,
that can undermine the internal validity of the
trial.246–248 An alternative that has been suggested
is to retain individual randomisation and accept
some contamination. This has the advantage that
for a given sample size a smaller difference
between groups could be observed in an
individually randomised trial compared with a
cluster study. This smaller difference would take
account of some dilution due to contamination.
Indeed, the power advantages of individual
randomisation are not eroded until contamination
is fairly high (>30% in some instances).249 There
is a problem with this approach, which relates to
the difference between statistical significance,
clinical significance and cost-effectiveness. The
advantages of individual randomisation that have
been discussed so far relate to statistical
significance. Even if the difference between the
groups is statistically significant, it may not be
clinically significant – the effect size is reduced
due to dilution bias. Furthermore, even if clinically
significant, the difference may not be cost-
effective, but may have been cost-effective had we
been able to observe the ‘true’ difference unbiased
by contamination. Therefore, in the likely
presence of contamination, some trialists may still
feel justified in undertaking a cluster randomised
controlled trial in order to gain a less precise but
unbiased estimate instead of a more precise but
diluted estimate, as would occur if ITT were used
in an individual randomised trial where there was
significant contamination. To retain individual
randomisation when we know there has been some
contamination, we require a statistical method that
produces an unbiased estimate of effect. 
Recently, a statistical method has been developed
which is known as the Complier Average Causal
Effect (CACE) or, in the economics literature, the
Local Average Treatment Effect (LATE).250–253
This is a measure of the average causal effect for
the subpopulation of adherers and, as it preserves
the initial randomisation it overcomes the
problems faced by per protocol analyses. This
approach has been advocated recently in the
statistical literature,254 but at present is not widely
used. The method used for non-adherence can
also be used for contamination, because both
problems entail misallocation of exposures to trial
subjects.
We will illustrate this approach with a trial of
faecal-occult-blood screening for the prevention of
colorectal cancer (CRC),255 which is shown in
Figure 31. The approach we use to deal with non-
adherence could also be used to deal with
contamination if the prevalence of contamination
was known. This very large randomised trial
showed a reduction of 15% in CRC mortality using
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rate for the first screening round. Therefore, there
is a fairly large dilution effect of screening
mortality. Although the trial answers the question
of ‘What would be the reduction in CRC mortality
if we offered population screening’, it does not
answer the question of what the reduction in
mortality would be if those who were offered
screening took up the offer. The authors of the
study realised the problem of contamination and
therefore undertook a per protocol analysis, where
they found a much larger benefit on deaths due to
CRC (39%). However, as the authors opted for a
per protocol analysis, this may be an overestimate
of the effect due to selection bias. In Figure 31 we
show the treatment profile of the faecal-occult-
blood screening study and demonstrate how
CACE analysis may work.256
From Figure 31, it can be seen that in the
intervention group there are two subgroups of
participants: those who take the treatment and
those who do not. One of the first assumptions
that we make about the CACE is that the control
group, had they been offered the treatment, would
have contained the same proportion of non-
adherers. Because we are using random allocation,
this statement must be true (except for chance
imbalances). The second assumption of CACE is
that merely being offered the treatment has no
effect on outcomes. If we accept that both of these
assumptions are true, then to obtain an unbiased
estimate of any treatment effect all we need to do
is to compare the observed outcomes in group Ai
with the unobserved outcomes in group Ac. We can
do this as follows.
From Figure 31, we can see that 47% of the
participants in the intervention group refused
screening and that 222 events occurred in this
population (i.e. 0.63%). We can also observe that
for the 40,214 participants that accepted the
screening 138 had an event (i.e. 0.34%). For the
control group, we cannot directly observe the
event rates in the potential adherers and non-
adherers groups. We do know, however, that the
total number of participants with the outcome of
interest was 420 in the control group. We can
assume that the control group will also contain
47% of participants who, if offered screening,
would refuse. If we assume that the offer of
treatment has no effect on the outcome, then we
can calculate that 222 of the 420 events must have
occurred among the 34,920 potential non-
adherers in the control group. This, then, leaves
198 remaining events that would have occurred in
the potential adherers group. We can now
compare the outcomes of those who accepted the
screening with a similar group who would have
accepted screening if they had been offered it. In
Table 26 the relative risks of the various
approaches are compared. 
As Table 26 shows, the ITT analysis produces the
highest relative risk and the per protocol
approach the lowest. The CACE method produces
an estimate that falls between these two extremes. 
This method has been expanded to allow for the
possibility of contamination, that is, use of the
intervention in the control group.257 To
demonstrate this, let us suppose that 20% of the
control group had in fact received faecal-occult-
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Intervention group (n = 75,253) Control group (n = 74,998)
Ai Observed adherers (n = 40,214)
Outcome (n = 138)
Ni Observed non-adherers (n = 35,039)
Outcome (n = 222)
Ti Total outcome = 360
Ac Potential adherers
Nc Potential non-adherers
Tc Total outcome = 420
Randomisation
FIGURE 31 Treatment profile of the faecal-occult-blood screening studyblood screening and also that 32 events occurred
in this group. Figure 32 shows a hypothetical
extension of the profile of the faecal-occult-blood
screening study. 
From Figure 32, we can see that among the
potential adherers in the control group there are
two subgroups of participants: those who seek
screening even though they have not been
randomised to receive screening and those who do
not. Let us assume that we observe that 20% of
participants in fact received faecal-occult-blood
screening in the control group and that 32 events
occurred in this population (i.e. 0.4%). We further
assume that we observe that for the 31,799
participants who did not seek screening in the
control group 166 had an event (i.e. 0.52%). Using
a similar argument as for the situation of non-
adherence, we can assume that the intervention
group will also contain 20% of participants who, if
allocated to the control group, would seek the
intervention. Consequently, we can calculate that
32 of the 138 events must have occurred among
the potential contaminators in the intervention
group. This then leaves 106 remaining events that
would have occurred in the potential non-
contaminators group. 
Table 27 shows that the ITT analysis produces the
highest relative risk and the CACE approach the
lowest. The per protocol analysis produces an
estimate that lies between the two. 
This was the simplest approach to CACE, but
many variables such as age will predict adherence.
Using these predictors in a regression analysis will
improve any point estimate because an unadjusted
CACE estimate suffers from two sources of
random variation: the initial random allocation
and the random variation within the study arms.
Also, using such predictors will enable a reduction
in the variance surrounding the CACE estimators
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TABLE 26 Comparison of relative risks between ITT, per protocol and CACE analysis for the colorectal cancer screening study
Intervention (n = 75,253) Control (n = 74,998)
Adherers (53%) Ai 138/40,214 = 0.34% Ac 198/39749 = 0.50%
Non-adherers (47%) Ni 222/35,039 = 0.63% Nc 222/35,249 = 0.63%
Total outcome Ti 360/75,253 = 0.48% Tc 420/74,998 = 0.56%
ITT analysis Ti/Tc = 0.85 (0.48%/0.56%)
Per protocol analysis  Ai/Tc = 0.61 (0.34%/0.56%)
CACE analysis Ai/Ac = 0.69 (0.34%/0.50%)
Ci Potential contaminators 
Randomisation
Control group (n = 74,998)
Ai Observed adherers (n = 40,214)
Outcome (n = 138)
Ac Potential adherers (n = 39,749)
Outcome (n = 198)
Cc Observed contaminators (n = 7950)
Outcome (n = 32)
Mc Potential contaminators (n = 31,799)
Outcome (n = 166)
Mi Potential non-contaminators
Intervention group (n = 75,253)
FIGURE 32 Hypothetical treatment profile of the faecal-occult-blood screening studyto be achieved; this is similar to the normal
adjusted two group analysis done routinely in
many randomised trials. There are a number of
statistical approaches to implementing CACE,
which do take account of the relationship between
predictors of adherence and outcome. In the
following sections, we have undertaken a review of
the different methods. 
Literature review of statistical
methods to take account of
contamination
Electronic searches were used to identify articles
that reported statistical methods to take account of
contamination in trials. A snowballing technique
was used to supplement the electronic searches.
References of studies that were included in the
review were checked and the ‘cited by’ function
was also used to find additional studies. 
Results
The search identified a number of papers that
described different methods or approaches to
CACE. The key literature identified from the
search is summarised below to give a brief
overview of the history of the techniques; however,
a full list of all of the included studies is available
on request from the authors.
Bloom, in the field of educational research, was
the first author we identified who reported
methods of adjusting estimates of treatment effects
to allow for non-adherence.251 Bloom concentrates
on the problem of ‘no-shows’, when some
participants in the treatment group fail to take the
treatment offered. In this simple instrumental
variable (IV) approach, the treatment effect
estimates are adjusted by considering the
proportion of non-adherers in the treatment
group. In the late 1980s and early 1990s, a
number of articles were published258–263 that
incorporated or expanded on this early work by
Bloom.251 An important milestone in the
formalisation of the IV technique was a
publication by Angrist and colleagues in 1996.250
They outlined a framework for the derivation of
an estimator based on Rubin’s Causal Model
(RCM)264,265 that allowed simple and easily
interpretable assumptions to be stated, which were
hidden in previous work (e.g. Bloom). 
The IV approach has been widely used in
economics when random allocation is not
possible.266 However, within an RCT with non-
adherence, treatment assignment (that is, the
groups to which the participants are randomised)
provides a perfect IV for confounding control.
Figure 33 illustrates the problems of contamination
in a typical trial. 
We are interested in estimating the effect of the
treatment on the outcome. However, when some
participants fail to receive their allocated
treatment, this relationship is likely to be
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TABLE 27 Comparison of relative risks between ITT, per protocol and CACE analysis for the hypothetical extension of the colorectal
cancer screening study
Intervention Control
Non-contaminators (80%) Mi 106/32,171 = 0.33% Mc 166/31,799 = 0.52%
Contaminators (20%) Ci 32/8,043 = 0.4% Cc 32/7,950 = 0.4%
Overall total outcome  Ti 360/75,253 = 0.48% Tc 420/74,998 = 0.56%
ITT analysis Ti/Tc = 0.85 (0.48%/0.56%)
Per protocol analysis  Ai/Mc = 0.66 (0.34%/0.52%)
CACE analysis Mi/Mc = 0.63 (0.33%/0.52%)
Treatment assignmentT reatment received Outcome 
Confounders
FIGURE 33 Contamination or non-adherence (treatment received differs from treatment assignment) in a typical trialconfounded by variables that influence the
treatment received and also the outcome. If it were
possible to identify all of the confounders then the
analysis could be conditioned on these variables,
thereby adjusting for the selection effects that
usually occur when on-treatment analysis is used.
However, it is likely, indeed probable, that some of
the confounders will be unmeasured or even
unimagined. Hence it is unlikely that the effect of
the treatment on the outcome can be measured in
an unconfounded manner using traditional
methods. Instrumental variable analysis requires
the identification of a variable that is independent
of all of the confounders, that is, associated with
the treatment received and has no direct effect on
the outcome itself.267 Since the groups are
randomised, the first assumption should be
satisfied. We would also hope that the treatment
the participants receive is affected by the
treatment to which the participants are
randomised; as there is some non-adherence, the
treatment received would not be fully determined
by the treatment assignment. Finally, we assume
that merely being offered the treatment has no
effect on outcomes. When these assumptions are
met, the treatment assignment acts as an IV and
the treatment effect can be estimated using the
equation originally proposed by Bloom251 or
alternatively by implementing a two-stage least
squares (2SLS) regression. The 2SLS regression
can be performed in most statistical software;
however, it involves regressing the treatment
received on the treatment assigned and saving the
predicted values, and then regressing the outcome
on the predicted values. The estimand of interest
is the predicted value coefficient. 
If we have a binary outcome then the IV
procedure has been shown to produce reasonable
estimates using 2SLS regression, but
bootstrapping is required to produce equivalent
estimates for the standard error.268 Sommer and
Zeger were the first to apply the IV methods in
the biostatistics literature for binary outcomes;256
although they state that Tarwotjo and colleagues
proposed the methods used.263 They derived risk
ratio estimators for the effect of the treatment
among the adherers in the intervention group and
the ‘would be’ treatment adherers in the control
group. Cuzick and colleagues257 extended the
method proposed by Sommer and Zeger256 to
allow for the possibility of contamination and
demonstrated this technique using data from
screening and prevention trials.
Nagelkerke and colleagues presented an IV
approach for dealing with non-adherence that is
slightly different to the IV approach described
above.252 However, similar estimates are obtained
to those when using Bloom’s equation directly or
by implementing a 2SLS regression, and also for
odds ratios or risk ratios similar estimates to those
obtained by the Sommer and Zeger method. 
From Figure 34, we can see that the treatment
assignment will affect the treatment received,
which will in turn affect the outcome of the trial
for each individual. However, the treatment
received will also be affected by other factors;
some of them will be random (e.g. error) and
others will be confounding variables, which affect
the treatment received and the outcome (e.g. age,
distance). Nagelkerke and colleagues defined a
variable E, which represents all of the other affects
on the treatment received except the treatment
assignment. This variable is used in lieu of having
the real confounders and included in a
multivariate analysis to adjust for the
confounding.
This method has the advantage that most types of
regression (linear, logistic, Poisson or Cox
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Treatment assignment Treatment received Outcome 
Variables influencing
outcome 
Confounders     Variables influencing
treatment received  
Effects of treatment
received (E) 
FIGURE 34 An approach to the problems of contamination or non-adherence (treatment received differs from treatment assigned) in
a typical trialproportional hazards model) can be used in the
analysis. Irrespective of the method used, the
treatment received variable and E (that is, all
other effects on the treatment received except
treatment assignment) are included as covariates
in the analysis. To implement this method, a two-
stage procedure is utilised. First, the treatment
received variable is regressed on the treatment
assignment variable and the residuals are saved;
the residuals represent the variable E. Finally, the
outcome is regressed on the treatment received
variable and the saved residuals from the first
regression. The estimand of interest is the
coefficient of the treatment received variable, as in
a conventional analysis. 
Likelihood-based estimation is another area of
research that has been explored to derive
estimates of CACE. Imbens and Rubin were
among the first to propose maximum likelihood
(ML) methods using the expectation maximisation
(EM) algorithm and Bayesian inference methods
using the data augmentation (DA) algorithm for
calculating CACE.269,270 The ML method has
subsequently been extended to incorporate
covariates that are predictive of the outcome and
adherence to treatment.271 In these methods, the
unknown adherence status in the control group is
treated as missing data. However, it has also been
proposed that the unknown adherence status of
the control group could be treated as a latent
variable within a structural equation model
framework.272 The adherence status is treated as a
categorical latent variable and the ML–EM
algorithm is used to estimate the unknown
adherence status of each individual participant in
the control group.
Application of the CACE approach
to trial data
To assess the utility of the CACE approach, we
applied one of the methods to two recently
published randomised trials, one looking at the
role of hip protectors for hip fracture prevention
and the other looking at dietary intervention for
the treatment of irritable bowel syndrome (IBS).
We chose these two trials for the following reasons:
first, we had access to the individual level data for
each trial; second, both trials suffered from a high
level of non-adherence. In this section, we
emphasise methods to deal with participants who
are randomised to receive the intervention but
who fail to adhere to the treatment and
subsequently ‘access’ the control group treatment.
As was noted in the section ‘Direct evidence of
contamination reported in trials of educational
interventions’ (p. 9), a large number of trials
report some degree of non-adherence whereas
very few report contamination. The methods we
show here to deal with non-adherence could also
be used to deal with contamination. Finally, we
wanted an example with a continuous outcome
measure and another with a binary measure. 
In this work, we primarily used Nagelkerke and
colleagues’ IV approach to calculate the CACE252
and used SPSS to implement this. Nagelkerke and
colleagues’ method is the simplest to apply with
commonly available statistical methods and
software (e.g. SPSS), and takes account of non-
random non-adherence. Other approaches using
slightly different statistical techniques generated
similar results when applied to these two trials. 
Trial 1: hip protector trial
The primary care hip protector trial is the largest
published randomised trial of hip protectors to
date.273 The main aim of this study was to assess
whether hip protectors used among women living
in the community and at high risk of hip fracture
led to a reduction in hip fracture. The study
included 4169 women, aged 70 years and older,
with one or more risk factors for hip fracture (i.e.
low body weight, current smoker, a prior fracture,
family history of hip fracture). The women in the
intervention group were mailed three pairs of hip
protectors with instructions on how to use them
and the control group received routine care.
Adherence with the hip protectors was poor, with
only 38% of participants reporting that they wore
them on a daily basis at 12 months. A total of
4129 participants were analysed in this paper after
listwise deletion of cases that had missing data.
The hip fracture rate among the control group
was 2.4% and among the intervention group 2.8%
(i.e. no difference between the groups). A key
criticism of the trial is that the observed lack of
benefit of the hip protectors could have been
because of poor adherence, which masked an
important effect among women who did use the
hip protectors as instructed. 
In Table 28 we show the results from the analyses
of the hip protector data using three different
approaches, that is ITT, per protocol and
Nagelkerke and colleagues’ CACE approach.
Although none of the results were statistically
significant, we can see that for the unadjusted
analysis the odds of experiencing a hip fracture
were slightly elevated in the protector group for
the ITT analysis. In the perprotocol analysis, the
risk of hip fracture appears to be reduced slightly
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However, the CACE results show a relative
increased risk of hip fracture, which is greater
than with either ITT or per protocol analysis (i.e.
1.64). 
In Table 28 we also present adjusted results. In
theory, we can make CACE more precise if we
identify not only the usual covariates for outcome
but also predictors of contamination. In this
instance, however, despite having statistically
significant predictors of adherence, the width of
the adjusted CIs for the adjusted CACE analysis,
although smaller than the unadjusted CACE CIs,
was still substantially wider than the ITT CIs.
By using the CACE approach, we can see that even
among women who claim to have been wearing hip
protectors ‘most of the time’ there is no evidence
of any benefit. Therefore, in this instance the
CACE approach strengthens the usual ITT method
of confirming a lack of benefit of hip protectors,
which suggests that non-adherence was not an
explanation for the negative findings of this trial.
Trial 2: dietary trial for irritable bowel
syndrome
The aim of the second randomised trial was to
assess the therapeutic potential of dietary
elimination based on the presence of IgG
antibodies to food among outpatients with IBS.274
Participants were randomised to receive either a
true diet that excluded all foods to which they had
raised IgG antibodies or a sham diet excluding the
same number of foods but not those to which they
had antibodies. Adherence with the diet was better
than the hip protector trial, as 70% of participants
reported that they adhered ‘moderately well’ or
‘completely’ to the diet at 12 weeks. Nevertheless,
a substantial proportion of participants did not
adhere to the diet as instructed. Therefore, the
ITT estimates are likely to underestimate the
benefit of dietary change on the symptoms of IBS
for those who adhere to the diet.
Change between groups in IBS symptom severity
score at 12 weeks, after adjusting for baseline
severity, was the main outcome measure. Table 29
shows the results from the IBS trial using the three
different approaches. Whereas the ITT analysis
suggests a small, statistically significant effect of
the true diet, the per protocol analysis suggests a
somewhat larger effect, which is highly statistically
significant. The CACE estimate lies between the
ITT and per protocol estimates. Note also in this
analysis that whereas both CACE and ITT are
statistically significant in their unadjusted analyses,
only CACE comes close to statistical significance in
the adjusted analysis.
In this instance, the clinician can now advise the
patient that if they adhere to the dietary
recommendations they can expect an
approximately 50-point improvement in symptom
severity. This contrasts with the ITT approach,
which would have underestimated the benefit for
the adherent participant, and the per protocol
estimate, which overestimates its effectiveness.
Note, however, that CACE produces the widest CIs
of the three approaches as it has two sources of
sample variance.
Summary of findings of examples
The application of CACE to these two trials
produced estimates of effect that we would expect
with complete adherence. For the IBS expected
study, our prior assumption was that ITT would
underestimate the diet’s effectiveness whereas per
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TABLE 28 Hip protector trial
Odds ratio Lower 95% CI Upper 95% CI p
Unadjusted
ITT 1.21 0.81 1.81 0.355
Per protocol 1.14 0.63 2.04 0.664
CACE 1.64 0.57 4.73 0.358
Adjusteda
ITT 1.19 0.79 1.78 0.401
Per protocol 1.10 0.61 1.98 0.751
CACE 1.50 0.55 4.09 0.425
a For outcome confounders, adjustments were age, prior fracture, history of falling and volunteer status, whereas for
predictors of adherence we adjusted for weight, smoking status and volunteer status. Adjustments were made using
individual patient data.protocol analysis would overestimate the
treatment’s effects. CACE, as expected, produced
an estimate that fell between these. In contrast, in
the hip protector trial, the CACE method showed
an increased risk of hip fracture using hip
protectors, albeit not statistically significant. 
Note that one important feature in these two
examples is that CACE tends to produce relatively
wide CIs. Thus, if we were in a situation of having
to choose between cluster randomisation and
individual allocation, then the CACE approach
may not offer much improvement in precision for
a given sample size. Nevertheless, choosing an
individual randomised trial with an a priori
specification of undertaking a CACE analysis
rather than a cluster trial lets us avoid some of the
methodological difficulties associated with
undertaking cluster trials. 
It seems to us that by using CACE methods we can
avoid the trade-off between individual and cluster
randomisation in terms of a biased estimate. Both
approaches however lose precision with a given
sample size. There will be trade-offs between the
methods depending upon the size of ICC, the
cluster size and the likely contamination rate.
Furthermore, there is a trade-off in terms of
variables that can predict adherence. If we can
identify strong predictors of adherence then some
of the imprecision of CACE can be avoided. In the
following section we have undertaken a simulation
study describing some of these likely trade-offs.
Simulation study
As noted earlier, one solution to the potential
problem of contamination is to randomise clusters
rather than individuals. However, when clusters
are randomised we suffer reduced power due to
the design effect, or variance inflation factor. The
design effect describes the extent to which the
sample size must be increased in order to obtain
the same power. It is given by
Deff = 1 + (m – 1) × ICC
where m is the mean cluster size. It can be seen
that if ICC is zero, the design effect is necessarily
zero. We also have potential problems when
implementing the design due to issues such as
inability to conceal allocation. The CACE method
highlighted above demonstrates one way to take
account of the problem of contamination;
however, a disadvantage of the CACE approach is
that it often produces wider CIs than an ITT
analysis and can do so for the per protocol
analysis. Hence we wanted to investigate the trade-
off between performing an individual randomised
trial and accepting the fact that there will be some
contamination, and the subsequent effect on the
precision of the estimate. Monte Carlo simulations
were used to investigate the use of Nagelkerke and
colleagues approach252 as an alternative to using
cluster allocation when contamination, through
non-adherence, is suspected. 
Monte Carlo simulation can reveal two different
effects on parameter estimates from different
treatments. First would be the increased variability
in parameter estimates when using one method as
opposed to another. The first effect will be the
variability of the estimates – in this the expected
value of the estimated parameter may be equal to
the true parameter value in all methods of
analysis, but the variability may be greater in one
method. The second effect is bias in the
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TABLE 29 IBS trial data
Estimate Lower 95% CI Upper 95% CI p Effect size
Adjusted for baseline severity only
ITT 33.67 0.51 66.83 0.047 0.36
Per protocol 60.48 23.96 97.00 0.001 0.66
CACE 49.22 4.14 94.31 0.033 0.56
Adjusteda
ITT 26.32 –6.74 59.38 0.118 0.30
Per protocol 53.35 15.50 91.20 0.006 0.60
CACE 40.47 –1.43 82.37 0.058 0.48
a For outcomes, we adjusted for baseline severity, symptom duration, proton pump inhibitor use, constipation predominant
group, total non-colonic features at visit 1 and the anxiety items of the Hospital Anxiety and Depression questionnaire,
whereas for adherence, we adjusted for baseline severity, sex, symptom duration and whether the participant was taking
antispasmodic drugs.parameter estimates – the expected value of the
parameter estimate is different (higher or lower)
than the true (population) value. It would be
expected that the treatment received analysis
would frequently give biased parameter estimates.
The other effect to examine is on the p-values of
the results. Here, the interest is in examining the
Type I error rate and power (Type II error rate).
When the null result is the case, we would expect
to find a Type I error rate equal to 5%, that is, we
make a false positive 5% of the time (given that we
are using  = 0.05). If the resultant error rate is
lower than 5%, then the test employed is over-
conservative (and has less power); if the error rate
is higher than this, the test is not sufficiently
stringent. We would expect that the treatment
received approach would have an inflated Type I
error rate, and that ITT analysis would have a
reduced Type I error rate. We would also expect
that the IV approach would give a type I error rate
which was approximately correct. Finally,
examination of the p-values can give us
information about the power of the test. Those
tests which are conservative with their Type I error
rate tend also to be less powerful than those tests
which are not conservative, hence we expect that
the treatment received approach will be more
powerful than ITT analysis. A major outcome of
this investigation will be to investigate the power
of the IV approach under a wide range of
circumstances.
Methods
The individual randomised trial was implemented
as follows:
● We described a set of hypothetical populations
in terms of the parameter values. Hence we
defined an effect size for the treatment, a
sample size and a level of contamination. 
● We generated 1000 samples that had the
specified parameter values.
● The samples were then analysed and the results
were compared with the known parameter
values from the populations. Data were analysed
using three different methods: treatment
received, ITT and Nagelkerke and colleagues’
CACE method.252
The cluster randomised trial was implemented as
follows:
● We described a set of hypothetical populations
in terms of the parameter values. Hence we
defined an effect size for the treatment, a
sample size and ICC.
● We generated 1000 samples that had the
specified parameter values.
● The samples were then analysed and the results
were compared with the known parameter
values from the populations.
For a CACE approach to deliver an unbiased
estimate compared with per protocol analysis, 
a covariate must correlate with adherence and
outcome, otherwise both analyses will give the
same result. In this instance, we used the baseline
test score as the appropriate covariate that
predicts both outcome and contamination. The
correlation coefficient that was used was 0.45 for
the outcome prediction. This value was taken from
the observed value in the IBS study.
Results
In Table 30 we show the effect of contamination on
the power of a study to detect a given effect size
with increasing rates of contamination. As can be
seen, with increasing contamination the power of
the study to detect a true difference between the
groups declines. The issue that confronts the
trialist is whether an alternative approach, namely
cluster randomisation, can be used that avoids
contamination and preserves study power. 
In Table 31 we illustrate the trade-off that
contamination has on the sample size needed to
detect a fixed effect size. As can be seen, as
contamination increases the sample size required
for 80% power increases. Table 31 also shows the
effect on sample size of switching to a cluster
design. Using a CACE approach, unless the
expected contamination exceeds 30%, retains a
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TABLE 30 Effect of contamination on the power of a study
Contamination (%)  Power with Nagelkerke method
Sample size = 630, true difference = 0.2 Sample size = 158, true difference = 0.4
0 0.80 0.80
10 0.74 0.72
20 0.64 0.61
30 0.54 0.54sample size advantage over the cluster randomised
design despite a relatively small cluster (i.e. 10)
and reasonably small ICC. 
These results are very similar to those found by
both Torgerson249 and Slymen and Hovell,275 who
advocated using ITT analysis and accepting some
contamination to show a diluted effect size. 
Discussion
Contamination, through non-adherence, is a
common problem in RCTs and creates problems at
the analysis stage. Although it is widely
recommended that the primary analysis of an
RCT should be using ITT, investigators often
supplement this with a per protocol analysis. The
main problem with a per protocol approach is that
as participants self-select themselves into the two
groups, the initial randomisation is undermined
and this consequently violates the basis for
statistical inference. In addition, the participants
who adhere to the treatment usually have different
characteristics from the participants who do not,
and this may introduce bias. 
We have demonstrated the use of the CACE
approach to calculate the treatment effects in two
recently published RCTs with some degree of 
non-adherence in the intervention group. A
disadvantage of the CACE approach is that it
produces wider CIs than an ITT analysis and can
do so for the per protocol analysis, as demonstrated
in the IBS example. However, in the examples
presented we did not include really strong
predictors of contamination. If there are strong
predictors of treatment contamination, these can 
be included in the analysis and can in some
instances substantially reduce the width of the CIs.
Nevertheless, the price of increasing the risk of a
Type II error compared with a per protocol
approach is, we feel, worth paying as it is better to
be approximately correct than precisely wrong,
which can be the outcome of a per protocol analysis. 
An alternative approach to using individual
randomisation and then using a CACE analytical
approach is to use cluster allocation. In our
simulation study we have shown that despite
CACE losing power relative to per protocol
analysis, it still has a power advantage over the
cluster design even when clusters are fairly small
and contamination relatively high. We
recommend, therefore, that if contamination can
be easily and accurately measured and is less than
30%, trialists should consider using individually
randomised designs as opposed to cluster
methods. In some instances this is not possible.
For example, Craven and colleagues undertook a
study looking at boosting children’s self-worth
through praise.276 In this study the authors used a
split plot design whereby they randomised at the
level of the classroom and then within the
intervention classes they randomised at the level
of the pupil. They found that although the teacher
was instructed not to give the intervention to the
control children in the class, they were often
unable to do this. This resulted in substantial
dilution within the intervention classes and
therefore the only reasonable solution would be to
cluster randomise. In this instance and in similar
types of studies (e.g. education of physicians in a
new treatment technique or guideline), CACE
Health Technology Assessment 2007; Vol. 11: No. 43
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TABLE 31 Sample sizes needed with cluster randomised trial and no contamination versus individual randomised trial using CACE to
adjust for contamination
True  Cluster  Total sample size needed  Contamination  Total sample size needed  Contamination 
difference size to have 80% power to  (%) to have 80% power to  effect
detect the true difference  detect the true difference 
between groups for a  between groups for an 
cluster randomised trial  individual randomised trial 
with ICC = 0.04 using CACE and including 
a covariate
0.2 10 1080 0 630 1
30 1740 10 756 1.20
50 2400 20 890 1.41
100 4000 30 1090 1.73
0.4 10 280 0 158 1
30 480 10 190 1.20
50 600 20 230 1.46
100 1000 30 276 1.75analysis would not offer any advantages as it would
not be possible to measure contamination
accurately at an individual level in order to control
for it in the analysis.
We suggest that although the ITT approach
should usually remain the primary analysis, some
form of CACE analysis should be performed as a
secondary analysis instead of a per protocol
analysis (or similar alternatives). There may also
be instances where CACE could be the primary
analysis in the presence of high levels of
contamination, when the main research question
concerns the individual patient.
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ontamination is often assumed to be a
problem in controlled trials of educational
interventions. It is commonly given as a reason for
using cluster randomisation, or as a reason why
effectiveness estimates were small or not
statistically significant. However, we have found
few studies in which contamination was recorded
and quantified, and no original trials in which it
was adjusted for statistically. Nevertheless,
substantial experience of educational trials in
health exists, and there is consensus on when
contamination is more or less likely to be a
problem. This study provides guidance on
situations where contamination is more or less
likely, how to avoid it when designing and
conducting trials and how to account for it when
analysing results. 
When designing a controlled trial of an
educational intervention in which contamination is
possible, one should systematically consider the
characteristics of the intervention, of the study
population and sample and of the geographical,
social and organisational contexts of the study.
First, can one avoid it during the trial by
restricting educational materials or by asking
intervention subjects to keep it to themselves?
How easily can the intervention be transmitted to
control subjects, as a whole or in parts? Is the
intervention unusual or desirable, so that control
subjects will hear about it and seek it? Will trial
participants actively disseminate it? If one were to
randomise clusters rather than individuals, how
might contamination still occur? Could the
intervention still reach control clusters and, if so,
how rapidly? Would it reach all subjects in control
clusters, or only a few, and how rapidly? Will
control subjects with unfavourable characteristics
at baseline be more, less or equally likely to be
contaminated? Our simulations in Chapter 4
suggest that, with different combinations of these
factors, the relative advantages of cluster and
individual randomisation vary. In many situations
cluster randomisation will reduce bias, but it may
increase bias, especially if entire clusters are
rapidly contaminated.
The choice between cluster and individual
randomisation should not only be based on
concerns about contamination. As stated by several
respondents to our Delphi study, the choice of
cluster randomisation is often primarily a logical
consequence of the level or unit of inference of
the trial, rather than a method of avoiding
contamination. For example, if an intervention 
to improve clinical practice is targeted at 
doctors, but effects are inferred by comparing
patients’ outcomes, then it makes sense to
randomise groups of patients managed by the
same doctors, who receive or do not receive an
intervention. In that way, doctors (and their
patients) in intervention and control groups are
comparable at baseline and any difference at
follow-up can be attributed to the effect of the
intervention on the doctors. If, instead, individual
patients are randomised to doctors who 
happened to have received the intervention or
not, then one cannot assume that the doctors are
comparable. Hence cluster randomisation may be
appropriate even if contamination is not a
problem.
If substantial contamination occurs and one knows
which control subjects have been contaminated,
then CACE or IV analysis seems likely to be more
valid than ITT or per protocol analysis, and is
more powerful than the latter. However, ITT
analysis, based on the groups to which subjects
have been initially randomised, should arguably
remain the primary method of analysis, with
CACE analysis the secondary method. This is
because of the assurance that randomisation
provides that the groups being compared were
identical, on average, regarding all characteristics,
including those that were not measured. Statistical
adjustment is unlikely to provide the same
assurance. However, if contamination is found to
have been common and intense, then CACE will
probably give less biased effect estimates. If a high
degree of contamination is expected before a trial,
so that CACE is likely to be most appropriate,
protocols should specify this in advance to be the
primary analytic method, so as to avoid scepticism
about having performed multiple analyses to
obtain a desired result. 
In trials in which contamination is likely, one
should wherever possible record, for each 
subject, whether and how it occurred. The most
obvious way is to add such questions to 
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Chapter 6
Conclusionsfollow-up questionnaires. If outcome is assessed
without personal contact, there may be creative
alternatives. For example, in a screening trial
reported in Chapter 2, control patients’ 
records were examined to see whether they 
had received the screening test. In a cluster
randomised nurse education trial we (MOB 
and others) were concerned that trained nurses
would be transferred from intervention to 
control clinics, so we checked the employment
records of control clinics for the trial period. 
None had. 
In summary, contamination is often a potential
problem but it may not be. It may be avoided
during the design or carrying out of the trial. If it
cannot be avoided it can be adjusted for, provided
that it is found. Therefore, contamination should
be recorded and reported in randomised trials of
educational interventions.
Conclusions
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Appendix 1
First-round Delphi questionnaire
Expressing your views:
The first round of this exercise seeks to determine your views as to the extent to which different types
of educational intervention study designs may be at risk of contamination. Some of the questions may
seem obvious, but as little previous work addresses this issue we need to see how much consensus exists
among experts. We ask you both to rank your agreement, and to add free comment about issues which
you consider important but which the format of ranking has not allowed you to address.
Given that many elements in a study may vary, we ask you to consider each answer as if other factors
were constant, that is, ‘all other things being equal’. So for example, when rating the risks of
contamination in trials of interventions aimed at improving skills, knowledge, behaviour or attitudes,
you need to abstract this from other features of the intervention such as complexity of intervention or
size of target audience. PLEASE CONSIDER THE ISSUE UNDER QUESTION AS IF IT WAS THE
ONLY COMPONENT WHICH COULD CAUSE CONTAMINATION.
(Click here for some definitions that you must read.)
Part 1 – Questions:
Q1 Educational interventions can focus on improving knowledge, altering skill set, changing
behaviours, or changing attitudes. For each of the following educational interventions please state
the likeliness of transfer of the intervention to controls:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Transfer of 
new knowledge
Transfer of 
new skills
Altering 
behaviours
Changing 
attitudesAppendix 1
94
Q2 Interventions can be defined as Simple, Modest and Complex. Please tell us for each of the
following designs the likeliness of contamination:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Simple – elements 
stand alone 
(a leaflet, 
a video)
Modest – some 
elements stand 
alone (the leaflet 
is backed up by a 
face to face 
training event)
Complex – multiple 
interdependent 
parts (trial 
participants meet 
monthly to practise 
their technical skills 
on a simulator 
hosted in a 
protected research 
environment)
Q3 Different communities of people may be involved in studies. Assuming that each named
category provides participants to both trial and control cohorts, what do you think the likelihood is
that contamination could occur if the intervention is:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Targeted at patients
Targeted at health 
professionals
Targeted at any 
section of the 
general populationHealth Technology Assessment 2007; Vol. 11: No. 43
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Q4 Please tell us the likelihood of contamination in the following situations where there is
movement between intervention and control locations:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Staff looking after 
patients in the 
intervention arm 
move to look after 
patients in the 
control arm
Patients at the 
intervention arm 
setting moving to 
the control arm 
setting
(If necessary click here to refer back to the definitions.)
Q5 Please tell us the likeliness of contamination where the controls and trials are:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
From the same 
geographical site
From nearby sites 
in same community
Geographically 
separated
Q6 Please tell us the likeliness of contamination where the controls and trials are:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
From same social 
networks
From overlapping 
social networks
Unlikely to have 
social networks in 
commonAppendix 1
96
(If necessary click here to refer back to the definitions.)
Q7 How likely is contamination where the intervention has:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Little desirability 
e.g. a set of 
statistical exercises 
to help patients 
understand risk
Medium desirability
High desirability 
e.g. a free video 
on exercise for 
weight loss
Q8 Please tell us the likeliness of contamination where the intervention is:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Easy to transfer
Difficult to transfer
Q9 Please tell us the likeliness of contamination where:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
No efforts are made 
to educate 
participants against 
contamination and 
how it could occur
Participants are 
educated to avoid 
contaminationHealth Technology Assessment 2007; Vol. 11: No. 43
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(If necessary click here to refer back to the definitions.)
Q11 Are there any situations which usually require cluster randomisation to avoid contamination?
(please specify which in the box below)
Q10 In the following types of study design how likely is it that contamination will occur?
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Individually 
randomised parallel 
group trial
Cluster randomised 
trial
Before/after 
comparisons
Repeated time 
series
(If necessary click here to refer back to the definitions.)
Q12 Educational studies may use different types of media to convey new information. For the
following types of media how likely is it that contamination will occur?
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Written information 
e.g. booklet
Audiovisual 
e.g. video, CD-ROM
Media output 
(TV, radio)
Training event 
(single attendance)
Training programme 
(multiple 
attendances)
Use of specialist 
resources (models, 
simulators)
Computer reminders 
(preset ‘popups’ on 
computer)
OtherAppendix 1
98
Q13 Different communities of people may be involved in studies. Assuming that each named
category provides participants to both trial and control cohorts, please tell us the likeliness of
contamination for each of the following:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Patients living in the 
same residence
Patients living in the 
same geographical 
locality
Patients with shared 
social networks
Patients whose 
healthcare comes 
from the same 
practice
(If necessary click here to refer back to the definitions.)
Q14 Similarly, if health professionals are the focus of studies, please tell us the likeliness of
contamination for each of the following:
Highly Moderately  Neither  Moderately  Highly No 
likely likely likely  nor  unlikely unlikely comment/
unlikely not sure
Health professionals 
sharing a place of 
employment
Health professionals 
in the same 
workplace team
Health professionals 
in the same clinical 
directorate or 
equivalent
Health professionals 
sharing an employerHealth Technology Assessment 2007; Vol. 11: No. 43
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Q15 To what extent do you agree that the following methods will be effective in avoiding
contamination:
Strongly  Tend to agree Neither  Tend to  Strongly  Don’t 
agree agree nor  disagree disagree know/NA
disagree
Avoid allocation of 
subjects to a less 
desirable arm 
(preference studies)
Geographical/social 
separation of subjects
Restriction on 
medium of 
intervention
Education of 
participants to 
avoid transfer of 
intervention
(If necessary click here to refer back to the definitions.)
Part 2 – Qualitative stage (please give examples/references from your own work if possible)
How do you think researchers can protect against contamination in controlled educational
intervention studies? 
(If necessary click here to refer back to the definitions.)
Part 3 – Comments about Round 1 of the Delphi
Do you have any comments about the responses you have given in the questionnaire?
Under which circumstances would you employ a particular study design specifically to avoid
contamination?
How would you know if contamination were occurring in a study?
Are there any ways in which we could increase the clarity of the questionnaire?
Do you accept our definitions of the relevant concepts? If not, how could we improve them?Appendix 1
100
Are there any key areas in contamination of educational interventions which we have not covered?
Additional information:
Please enter your details below (all responses will be kept anonymous)
Name: 
Email address: 
Job title: 
Relevant interest: 
Thank you for completing this survey. Click on the submit answers button to submit your answers. 
This may take a few seconds.Health Technology Assessment 2007; Vol. 11: No. 43
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Appendix 2
Second-round Delphi questionnaire
(If necessary click here to refer back to the definitions.)Appendix 2
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(If necessary click here to refer back to the definitions.)
(If necessary click here to refer back to the definitions.)
(If necessary click here to refer back to the definitions.)Health Technology Assessment 2007; Vol. 11: No. 43
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(If necessary click here to refer back to the definitions.)
(If necessary click here to refer back to the definitions.)Appendix 2
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DELPHI questionnaire – Contamination in trials of educational interventions
Some definitions:
Contamination: an intervention intended for members of the trial arm in a study being actively received
by some participants in the other (control) arm. This excludes cross-over between arms that is known to
the researchers and can be adjusted for, and excludes non-adherence, where participants have not
utilised the intervention to its full potential.
Mechanisms of contamination in educational trials could include, for example:
● educational media being passed on to members of the control group by trial arm participants 
● discussion between trained and untrained subjects 
● transfer of trained and untrained people between intervention and control sites. 
Educational interventions: one or more methods to alter their knowledge, skills and/or behaviours.
Single faceted intervention: one component only, e.g. a leaflet, a single nurse contact.
Multi-faceted intervention: whole intervention includes more than one component, e.g. a training
meeting PLUS written handbook PLUS a follow-up visit to check progress.
Major risk: contamination is so likely to occur that cluster randomisation should be considered instead of
individual randomisation.
Cluster randomisation: the randomised allocation of a group of participants to one or other arms of a
study.
Intraclass correlation: the extent to which characteristics of participants in one cluster or group are
acting independently or not.
Individually randomised parallel group trial: a trial that compares two groups of subjects, one of which
receives the intervention of interest and one of which is a control group. The allocation of subjects to the
control or intervention arm is made by randomly allocating each subject to a treatment group and
following them up at the same time.
Controlled before and after study (CBA): CBAs incorporate a non-randomised control group that, it is
hoped, will experience the same secular and sudden changes as the intervention group. Data are
collected on the control and intervention groups before the intervention is introduced and then further
data are collected after the intervention has been introduced. Also known as a quasi-experiment.
Repeated or interrupted time series (RTS/ITS): the repeated time series design involves repeated
measurement of trial subjects over time, encompassing periods both prior to and after implementation of
the intervention. The goal of such an analysis is to assess whether the treatment has ‘interrupted’ or
changed a pattern established prior to the trial’s implementation.
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